Membrane-enhanced field-effect transistor (MEFET) sensor

WO2026236099A1PCT designated stage Publication Date: 2026-11-12UNIV OF NOTRE DAME DU LAC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026491
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-05
Filing Date
2026-05-04
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Field-effect transistor (FET) sensors face challenges in detecting nanocarriers such as extracellular vesicles and uncharged molecules in physiological samples due to Debye layer screening, batch-to-batch variability, and interference from healthy cell nanocarriers, requiring high-vacuum deposition and limited flexibility in modifying the sensing interface.

Method used

A membrane-enhanced FET biosensor platform with an ion exchange membrane (IEM) generates an ion depletion zone near the sensing electrode, reducing local ionic strength and increasing the Debye length, combined with multi-marker detection using charged reporter particles to enhance sensitivity and specificity.

Benefits of technology

The platform achieves improved detection sensitivity and reliability for nanocarriers in physiological samples without pretreatment, reducing interference from healthy cell nanocarriers and maintaining compatibility with scalable manufacturing processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000052_0001_TABLE
    Figure IMGF000052_0001_TABLE
  • Figure 00000073_0000
    Figure 00000073_0000
  • Figure 00000073_0001
    Figure 00000073_0001
Patent Text Reader

Abstract

Described herein are biosensor systems, devices, and methods for detecting target analytes and biomolecules with enhanced sensitivity. In various aspects, the biosensor devices comprise a field-effect transistor (FET) and a sensing electrode electrically connected to a gate terminal of the FET, the sensing electrode being configured to capture target analytes directly or indirectly. The biosensor device may be configured to detect target analytes based on a change in an electrical characteristic of the FET. The biosensor device may further comprise an ion exchange membrane to generate an ion depletion zone proximate to the sensing electrode. Also described herein are methods and devices for isolating, detecting, or quantifying nanocarriers that co-express at least two distinct surface markers using a FET readout. This multi-marker nanocarrier detection approach may use charged reporter particles with or without an ion exchange membrane or ion depletion.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] 092012-0079-W001

[0002] MEMBRANE-ENHANCED FIELD-EFFECT TRANSISTOR (MEFET) SENSOR

[0003] CROSS-REFERENCE TO RELATED APPLICATION(S)

[0004] This application claims priority to U. S. Provisional Patent Application No. 63 / 800,295, filed on May 5, 2025, which is incorporated by reference herein in its entirety.

[0005] FEDERALLY SPONSORED RESEARCH

[0006] This invention was made with government support under R21 AI180713 awarded by the National Institutes of Health (NIH). The government has certain rights in the invention.

[0007] REFERENCE TO SEQUENCE LISTING

[0008] This application was filed with a Sequence Listing XML in ST.26 XML format in accordance with 37 C. F. R. § 1.831 and PCT Rule 13ter. The Sequence Listing XML file submitted in the USPTO Patent Center, “092012-0079-W001_sequence_listing_XML_1-APR-2026.xml,” was created on April 1, 2026, contains 7 sequences, has a file size of 7.13 kilobytes (7,309 bytes), and is incorporated by reference in its entirety into the specification.

[0009] BACKGROUND

[0010] Field-effect transistor (FET) sensors represent a class of semiconductor-based detection platforms that transduce electrochemically generated charge into measurable electrical signals. These sensors have gained considerable attention in biosensing applications due to their potential for label-free detection, scalability, and compatibility with standard semiconductor fabrication methods. Two configurations of FET sensors that can be commercially fabricated at large scales include extended-gate FET (EGFET) and solution-based organic FET (OFET) devices.

[0011] Recent developments in two-dimensional semiconducting materials, such as graphene, molybdenum disulfide (MoS2), and MXene, have demonstrated detection capabilities reaching attomolar concentrations. These materials exhibit carrier mobility characteristics and surface-to-volume ratios that enable sensitive modulation of channel conductance in response to charge perturbations at the gate interface. However, FET devices based on two-dimensional materials present challenges for large-scale fabrication, often requiring high-vacuum deposition, transfer processes, or lithographic precision that can introduce batch-to-batch variability. Additionally, these platforms are typically not reusable and offer limited flexibility in modifying the sensing interface once fabricated, which can limit their translation into low-cost, disposable diagnostic tools.092012-0079-W001

[0012] There is interest in extending EGFET and OFET technologies to biosensing applications for the detection of nucleic acids, proteins, and extracellular vesicles in physiological samples. Detection of nanocarriers such as lipoproteins, exosomes (extracellular vesicles), supermeres, and exomeres are particularly important, as many disease biomarkers are released by diseased cells as cargoes of the nanocarriers, which are much larger than the molecular biomarkers. However, FET sensors operating in high-ionic strength physiological samples face challenges related to fluctuations in ionic strength and Debye layer screening effects. The Debye layer, which characterizes the distance over which electrostatic effects persist in an ionic solution, becomes compressed at higher ionic strengths typical of physiological fluids. This compression can reduce the effective coupling between charged biomolecules and the sensing surface, thereby affecting detection sensitivity. As the Debye layer for physiological fluids is often about 1 nm, it completely screens the signal from larger nanocarriers like extracellular vesicles with dimensions larger than 50 nm. Pretreatment efforts to isolate and purify the analytes prior to detection by the biosensing and exchange the original buffer with a low-ionic strength with minimal Debye screening often leads to undesirable analyte loss.

[0013] There is also a need to extend FET biosensor platforms to uncharged molecules and nanoparticles. This usually requires a charge reporter that has high affinity to accommodate the high sensitivity of FET sensors. Labeling of optical reporters often leads to false positives due to non-specific adsorption. Thus, the charge reporters must avoid non-specific binding to achieve sensitive detection.

[0014] Recent work has shown that many molecular biomarkers in physiological fluids are carried as cargoes of nanoparticles such as extracellular vesicles, ribonucleoproteins, exomeres, and supermeres. These nanocarriers are secreted by both diseased cells and healthy cells. They are also secreted at different rates depending on the cell metabolism and external stimuli. Isolating only nanocarriers from diseased cells would achieve more sensitive disease diagnosis. In addition, quantifying the nanocarriers before assaying their biomarker cargoes would allow normalization to account for fluctuations in nanocarrier production. Most of the nanocarriers are weakly charged and hence their FET detection would also need charge reporters.

[0015] Biomarkers of nanocarriers from diseased cells are often also expressed on healthy cells. Although the biomarkers are under-expressed on healthy cells, the healthy cells outnumber the diseased cells significantly. Therefore, nanocarriers from healthy cells will often interfere with assay efforts of nanocarriers from diseased cells.

[0016] What is needed are FET biosensor platforms that can provide improved detection sensitivity for nanocarriers such as extracellular vesicles and reliability when operating with092012-0079-W001

[0017] physiological samples, without pretreatment, while also maintaining compatibility with scalable manufacturing processes, and being free from interference by nanocarriers from healthy cells.

[0018] SUMMARY

[0019] One embodiment described herein is a biosensor device, comprising: a field-effect transistor (FET) comprising a gate terminal, a source terminal, and a drain terminal; and a sensing electrode electrically connected to the gate terminal of the FET, the sensing electrode configured to capture a target analyte directly or indirectly; wherein the biosensor device is configured to detect the target analyte based on a change in an electrical characteristic of the FET. In one aspect, the FET comprises an n-type enhancement mode metal-oxide-semiconductor FET (MOSFET). In another aspect, the sensing electrode comprises a gold electrode. In another aspect, the gold electrode comprises a titanium adhesion layer and a gold layer deposited on the titanium adhesion layer. In another aspect, the target analyte comprises a nanocarrier. In another aspect, the nanocarrier comprises an extracellular vesicle, exomere, supermere, lipoprotein, virus, or combinations thereof. In another aspect, the sensing electrode is configured to capture the target analyte using a first binding moiety specific for a first marker. In another aspect, the biosensor device is configured to detect the target analyte using a second binding moiety specific for a second marker on the same target analyte. In another aspect, the target analyte is a nanocarrier that co-localizes the first marker and the second marker. In another aspect, the second binding moiety is associated with a charged reporter particle. In another aspect, the charged reporter particle comprises a magnetic particle or a non-magnetic silica particle. In another aspect, the charged reporter particle is configured to modulate the electrical characteristic of the FET when positioned proximate to the sensing electrode to quantify the target analyte. In another aspect, the biosensor device is configured to detect the target analyte using a third binding moiety specific for a third marker on the same target analyte. In another aspect, the electrical characteristic comprises one or more of drain current, threshold voltage, transconductance, or a transfer characteristic curve. In another aspect, the FET is operated in a subthreshold regime. In another aspect, the biosensor device further comprises a microfluidic channel positioned adjacent to the sensing electrode. In another aspect, the biosensor device further comprises an ion exchange membrane positioned within or adjacent to the microfluidic channel. In another aspect, the biosensor device further comprises one or more electrodes configured to apply an electric field across the ion exchange membrane to generate an ion depletion zone proximate to the sensing electrode. In another aspect, the sensing electrode is functionalized with probe molecules at a high density to selectively bind the target analyte with092012-0079-W001

[0020] high affinity. In another aspect, the probe molecules comprise one or more antibodies or nucleic acid probes. In another aspect, the target analyte comprises microRNA sequences and the nucleic acid probes are configured to hybridize with the microRNA sequences.

[0021] Another embodiment described herein is a biosensor device, comprising: a field-effect transistor (FET) comprising a gate terminal, a source terminal, and a drain terminal; a sensing electrode electrically connected to the gate terminal of the FET, the sensing electrode configured to capture target biomolecules; a microfluidic channel positioned adjacent to the sensing electrode; an ion exchange membrane (IEM) positioned within the microfluidic channel; and a pair of electrodes configured to apply an electric field across the IEM to generate an ion depletion zone in a region of the microfluidic channel proximate to the sensing electrode. In one aspect, the IEM comprises a cation exchange membrane. In another aspect, the cation exchange membrane comprises sulphonate ion-exchange groups. In another aspect, the IEM comprises an anion exchange membrane. In another aspect, the biosensor device further comprises a pair of buffer reservoirs positioned at opposite ends of the microfluidic channel, wherein the IEM is positioned beneath at least one of the buffer reservoirs. In another aspect, the pair of electrodes comprises platinum electrodes positioned within the buffer reservoirs. In another aspect, the ion depletion zone is configured to reduce local ionic strength from about 150 mM to below about 0.001 mM.

[0022] Another embodiment described herein is a method for detecting or quantifying target nanocarriers, the method comprising: contacting a sample comprising nanocarriers with a first binding reagent specific for a first marker; capturing target nanocarriers expressing the first marker; contacting the captured target nanocarriers with a second binding reagent specific for a second marker; and measuring an electrical characteristic of a field-effect transistor (FET) to detect or quantify target nanocarriers that co-localize the first marker and the second marker on the same nanocarrier. In one aspect, the second binding reagent is associated with a charged reporter particle. In another aspect, the charged reporter particle comprises a magnetic particle or a non-magnetic silica particle. In another aspect, the method further comprises washing to remove nonspecifically associated reporter particles prior to measuring the electrical characteristic. In another aspect, the nanocarriers comprise extracellular vesicles. In another aspect, measuring the electrical characteristic comprises measuring drain current as a function of gate voltage. In another aspect, the FET is operated in a subthreshold regime. In another aspect, the method further comprises releasing, cleaving, or dissociating the nanocarriers after detecting the first marker and the second marker, and re-capturing or re-detecting the nanocarriers using a third binding reagent specific for a third marker. In another aspect, the092012-0079-W001

[0023] method further comprises lysing the detected or quantified nanocarriers and measuring one or more cargo molecules. In another aspect, the quantified nanocarriers are used to normalize the one or more cargo molecules. In another aspect, the method further comprises generating an ion depletion zone proximate to a sensing electrode by applying an electric field across an ion exchange membrane, wherein the sensing electrode is electrically connected to a gate terminal of the FET.

[0024] Another embodiment described herein is a method for detecting a target analyte, the method comprising: providing a biosensor device comprising a field-effect transistor (FET) having a sensing electrode electrically connected to a gate terminal of the FET; introducing a sample containing the target analyte into the biosensor device; capturing the target analyte on the sensing electrode; and measuring an electrical characteristic of the FET to detect the target analyte. In one aspect, the target analyte comprises a microRNA. In another aspect, the microRNA comprises at least one of miR-21, miR-9, or miR-101-5p. In another aspect, the target analyte comprises a nanocarrier. In another aspect, the nanocarrier comprises extracellular vesicles. In another aspect, the extracellular vesicles are detected using one or more charged reporter particles. In another aspect, the extracellular vesicles comprise surface proteins comprising CD63, CD81, or a combination thereof. In another aspect, the surface proteins of the extracellular vesicles comprise disease-associated protein biomarkers. In another aspect, measuring the electrical characteristic of the FET comprises measuring a transfer characteristic curve by sweeping a gate voltage while maintaining a fixed drain-source voltage. In another aspect, measuring the transfer characteristic curve comprises operating the FET in a subthreshold regime. In another aspect, the biosensor device further comprises a microfluidic channel positioned adjacent to the sensing electrode, and an ion exchange membrane (IEM) positioned within or adjacent to the microfluidic channel. In another aspect, the method further comprises applying an electric field across the IEM to generate an ion depletion zone proximate to the sensing electrode. In another aspect, applying the electric field comprises applying a DC voltage of about 5 V to about 200 V across the IEM. In another aspect, the method further comprises incubating the sample on the sensing electrode for a period of about 30 minutes to about 60 minutes prior to applying the electric field. In another aspect, generating the ion depletion zone reduces local ionic strength from about 150 mM to below about 0.001 mM, thereby increasing an effective Debye length to greater than about 100 nm.

[0025] Another embodiment described herein is a biosensor system, comprising: a biochip comprising a chip substrate, an inlet, an outlet, and a plurality of sensors; a field-effect transistor (FET) electrically connected to at least one of the plurality of sensors; and a measurement circuit092012-0079-W001

[0026] configured to measure drain current of the FET as a function of gate voltage. In one aspect, the biochip further comprises a microfluidic channel extending between the inlet and the outlet, at least one buffer reservoir, and an ion exchange membrane (IEM) positioned beneath the at least one buffer reservoir, the plurality of sensors being positioned within the microfluidic channel. In another aspect, the biosensor system further comprises a voltage source configured to apply an electric field across the IEM to generate an ion depletion zone within the microfluidic channel. In another aspect, the biochip comprises a pair of buffer reservoirs positioned at opposite ends of the microfluidic channel, and wherein the IEM comprises a cation exchange membrane or an anion exchange membrane positioned beneath each of the buffer reservoirs. In another aspect, the biosensor system further comprises platinum electrodes positioned within the pair of buffer reservoirs and configured to receive a DC voltage of about 5 V to about 200 V from a voltage source. In another aspect, the plurality of sensors comprises gold electrodes functionalized with probe molecules configured to selectively bind target biomolecules. In another aspect, the probe molecules comprise at least one of nucleic acid probes or antibodies. In another aspect, the measurement circuit is configured to operate the FET in a subthreshold regime to maximize sensitivity to surface charge perturbations induced by biomolecular binding events.

[0027] Another embodiment described herein is a method for enhancing sensitivity of a fieldeffect transistor (FET) biosensor, the method comprising: providing a FET biosensor having a sensing electrode functionalized with probe molecules for capturing target biomolecules; positioning an ion exchange membrane (IEM) within a microfluidic channel adjacent to the sensing electrode of the FET biosensor; introducing a sample into the microfluidic channel; and applying an electric field across the IEM to deplete ions from a region proximate to the sensing electrode, thereby increasing an effective Debye length and enhancing electrostatic coupling between the target biomolecules and the sensing electrode. In one aspect, applying the electric field comprises applying a DC voltage of about 5 V to about 200 V across the IEM. In another aspect, depleting ions from the region proximate to the sensing electrode reduces local ionic strength from about 150 mM to below about 0.001 mM. In another aspect, the effective Debye length is increased to greater than about 100 nm. In another aspect, the probe molecules comprise at least one of nucleic acid probes configured to hybridize with target microRNA sequences or antibodies configured to bind target protein markers. In another aspect, the method further comprises measuring a transfer characteristic curve of the FET biosensor by sweeping a gate voltage while maintaining a fixed drain-source voltage, wherein the FET biosensor is operated in a subthreshold regime to maximize sensitivity to surface charge perturbations.092012-0079-W001

[0028] Another embodiment described herein is the use of a biosensor device for detecting target biomolecules in a physiological sample, the biosensor device comprising a field-effect transistor (FET) having a sensing electrode, a microfluidic channel, and an ion exchange membrane (IEM), wherein an electric field is applied across the IEM to generate an ion depletion zone proximate to the sensing electrode to reduce ionic strength and extend Debye length during detection. In one aspect, the target biomolecules are charged and comprise at least one of microRNA, extracellular vesicles (EVs), supermeres, exomeres, lipoproteins, proteins, or viruses.

[0029] DESCRIPTION OF THE DRAWINGS FIG. 1A shows a schematic showing FET coupled with a depletion module. FIG. 1B shows a picture of an exemplary biochip containing an inlet, buffer reservoir, ion exchange membranes, sensors, and an outlet. FIG. 1C shows a schematic of the biochip of FIG. 1B.

[0030] FIG. 2 shows a transfer characteristic curve, where / D = ( / O- / D) / / O.

[0031] FIG. 3 shows calibration curves of 1x PBS condition, 0.1X PBS condition, and depletion-induced condition for miR-101-5p.

[0032] FIG. 4 shows the limit of detection (LoD) of miR-101-5p for different conditions, using depletion increases LoD by 4-5 orders of magnitude compared to 1x PBS (physiological) condition with miR-101-5p.

[0033] FIG. 5 shows a transfer curve of miR-101-5p under 1X PBS condition.

[0034] FIG. 6 shows a transfer curve of miR-101-5p under 0.1x PBS condition.

[0035] FIG. 7 shows a transfer curve of miR-101-5p using the depletion module with miR-9. FIG. 8 shows a transfer curve of miR-9 using the depletion module.

[0036] FIG. 9 shows a calibration plot of miR-9 under depletion condition.

[0037] FIG. 10A-C show the signal measurement under different electrode corrections. FIG. 10A shows a single electrode. FIG. 10B-C show 4 separate electrodes. Neighboring electrodes did not measurably influence the signal of the active sensing electrode. No detectable crosstalk was observed in the design.

[0038] FIG. 11 shows the sensor selectivity when sensors were functionalized with miR-9 and miR-21 probes and treated with complementary miR-9 and miR-21 sequences. Only a perfect matching probe and target yielded a significant shift.

[0039] FIG. 12A-D show mismatch studies with the miR-9 sequence. FIG. 12A shows the shifts observed at different mismatches. FIG. 12B-D show the signals for different mismatches, 1 mismatch (FIG. 12B); 2 mismatches (FIG. 12C); and 3 mismatches (FIG. 12D).092012-0079-W001

[0040] FIG. 13A-C show the detection of CD63+ EVs and HSPA13+ supermeres when DiFi cell media samples were exposed to sensors attached to anti-CD63 and anti-HSPA13 probes. FIG.

[0041] 13A-B show results for supermeres and DiFi EVs. FIG. 13C shows a plot of A / D.

[0042] FIG. 14A-E show the successful detection of 2 co-localized EV protein markers (CD63 and CD81). FIG. 14A shows a scheme of the detection process. FIG. 14B shows results for CD63. FIG. 14C shows results for CD63 and CD81. FIG. 14D shows a plot of A / Dversus the wash step. FIG. 14E shows a box and wisker plot of the results for CD63 and CD81.

[0043] FIG. 15 illustrates a block diagram of an exemplary biosensor system, according to aspects of the present disclosure.

[0044] FIG. 16 illustrates a block diagram of an exemplary biosensor device, according to aspects of the present disclosure.

[0045] FIG. 17 illustrates a flowchart for an exemplary method for detecting a target analyte, according to aspects of the present disclosure.

[0046] FIG. 18 illustrates a flowchart for an exemplary method for enhancing sensitivity of a fieldeffect transistor biosensor, according to aspects of the present disclosure.

[0047] FIG. 19 illustrates a flowchart for an exemplary method for detecting a target analyte using a biosensor device as disclosed herein, according to aspects of the present disclosure.

[0048] FIG. 20 illustrates a flowchart for an exemplary method for enhancing sensitivity of a fieldeffect transistor biosensor with subthreshold regime operation, according to aspects of the present disclosure.

[0049] DETAILED DESCRIPTION

[0050] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. For example, any nomenclatures used in connection with, and techniques of biochemistry, molecular biology, and chemistry described herein are well known and commonly used in the art. In case of conflict, the present disclosure, including definitions, will control the interpretation of terms. Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can be used in practice or testing of the embodiments and aspects described herein.

[0051] As used herein, terms such as “include,” “including,” “contain,” “containing,” “having,” and the like mean “comprising.” The present disclosure also contemplates other embodiments “comprising,” “consisting essentially of,” and “consisting of” the embodiments or elements presented herein, whether explicitly set forth or not. As used herein, “comprising,” is an “open-092012-0079-W001

[0052] ended” term that does not exclude additional, unrecited elements or method steps. As used herein, “consisting essentially of” limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristics of the claimed invention. As used herein, “consisting of” excludes any element, step, or ingredient not specified in the claim.

[0053] As used herein, the term “a,” “an,” “the” and similar terms used in the context of the disclosure (especially in the context of the claims) are to be construed to cover both the singular and plural unless otherwise indicated herein or clearly contradicted by the context. In addition, “a,” “an,” or “the” means “one or more” unless otherwise specified.

[0054] As used herein, the term “or” can be conjunctive or disjunctive.

[0055] As used herein, the term “and / or” refers to both the conjunctive and disjunctive.

[0056] As used herein, the term “substantially” means to a great or significant extent, but not completely.

[0057] As used herein, the term “about” or “approximately” as applied to one or more values of interest, refers to a value that is similar to a stated reference value, or within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, such as the limitations of the measurement system. In one aspect, the term “about” refers to any values, including both integers and fractional components that are within a variation of up to ± 10% of the value modified by the term “about.” Alternatively, “about” can mean within 3 or more standard deviations, per the practice in the art. Alternatively, such as with respect to biological systems or processes, the term “about” can mean within an order of magnitude, in some embodiments within 5-fold, and in some embodiments within 2-fold, of a value. As used herein, the symbol means “about” or “approximately.” All ranges disclosed herein include both end points as discrete values as well as all integers and fractions specified within the range. For example, a range of 0.1-2.0 includes 0.1, 0.2, 0.3, 0.4... 2.0. If the end points are modified by the term “about,” the range specified is expanded by a variation of up to ±10% of any value within the range or within 3 or more standard deviations, including the end points, or as described above in the definition of “about.”

[0058] As used herein, the terms “room temperature,” “RT,” or “ambient temperature” refer to the typical temperature in an indoor laboratory setting. In one aspect, the laboratory setting is climate controlled to maintain the temperature at a substantially uniform temperature or with a specific range of temperatures. In one aspect, “room temperature” refers a temperature of about 15-30 °C, including all integers and endpoints within the specified range. In another aspect, “room temperature” refers a temperature of about 15-30 °C; about 20-30 °C; about 22-30 °C; about 25-30 °C; about 27-30 °C; about 15-22 °C; about 15-25 °C; about 15-27 °C; about 20-22 °C;092012-0079-W001

[0059] about 20-25 °C; about 20-27 °C; about 22-25 °C; about 22-27 °C; about 25-27 °C; about 15 °C ± 10%; about 20 °C ± 10%; about 22 °C ± 10%; about 25 °C ± 10%; about 27 °C ± 10%; ~20 °C, ~22 °C, ~25 °C, or ~27 °C, at standard atmospheric pressure.

[0060] As used herein, the terms “control,” or “reference” are used herein interchangeably. A “reference” or “control” level may be a predetermined value or range, which is employed as a baseline or benchmark against which to assess a measured result. “Control” also refers to control experiments or control cells.

[0061] As used herein, the terms “amino acid,” “nucleotide,” “polynucleotide,” “vector,” “polypeptide,” and “protein” have their common meanings as would be understood by a biochemist of ordinary skill in the art. Standard single letter nucleotides (A, C, G, T, U) and standard single letter amino acids (A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, or Y) are used herein.

[0062] As used herein, the term “field-effect transistor” or “FET” refers to a semiconductor device in which current flow between a source terminal and a drain terminal is controlled by an electric field applied to a gate terminal, including metal-oxide-semiconductor field-effect transistors (MOSFETs), organic field-effect transistors (OFETs), and extended-gate field-effect transistors (EGFETs).

[0063] As used herein, the term “sensing electrode” refers to a conductive element electrically connected to the gate terminal of a field-effect transistor and configured to capture target biomolecules, which may be functionalized with probe molecules for selective binding of target analytes.

[0064] As used herein, the term “ion exchange membrane” or “I EM” refers to a permselective membrane that selectively transports certain ion species while rejecting others based on charge, including cation exchange membranes that allow cation transport and reject anions, and anion exchange membranes that allow anion transport and reject cations.

[0065] As used herein, the term “ion depletion zone” refers to a localized region of reduced ionic strength formed adjacent to an ion exchange membrane when an electric field is applied across the membrane, resulting from selective ion transport through the membrane.

[0066] As used herein, the term “microfluidic channel” refers to a fluid pathway having dimensions on the micrometer (pm; micron) scale configured to transport sample fluids and enable contact between sample components and sensing elements.

[0067] As used herein, the term “probe molecules” refers to molecules functionalized on a sensing electrode surface that are configured to selectively bind target biomolecules, including,092012-0079-W001

[0068] for example, nucleic acid probes configured to hybridize with complementary nucleic acid sequences and antibodies configured to bind specific protein markers.

[0069] As used herein, the terms “target biomolecule” or “target analyte” are used interchangeably and refer to biological molecules, analytes, or particles to be detected, including, but not limited to, nucleic acids, messenger RNA (mRNA), microRNA (miRNA), proteins, extracellular vesicles (EVs), supermeres, exomeres, lipoproteins, viruses, and / or other nanocarriers of biomarkers.

[0070] As used herein, the term “nanocarriers” refers to nanoparticles and vesicles that carry biomarkers. Non-limiting examples of nanocarriers include extracellular vesicles, exomeres, exosomes, supermeres, microvesicles, apoptotic bodies, lipoprotein particles, viruses, virus-like particles, protein-based nanoparticles, or cell-membrane-derived vesicles, wherein the biological nanocarrier encapsulates, displays, associates with, or otherwise carries one or more biomarkers. In some embodiments, a nanocarrier is a target analyte or target biomolecule.

[0071] As used herein, the term “multi-marker” refers to identification, isolation, enrichment, detection, and / or quantification of a target nanocarrier based on the presence of at least two distinct markers associated with the same nanocarrier.

[0072] As used herein, the term “co-localized” refers to two or more distinct markers being present on the same individual nanocarrier, rather than on separate particles in the same sample.

[0073] As used herein, the term “charged reporter particle” refers to a particle carrying net charge sufficient to modulate an electrical characteristic of a field-effect transistor when positioned proximate to a sensing electrode, optionally wherein the particle is conjugated to a binding moiety specific for a target analyte or target-associated marker.

[0074] As used herein, the term “binding moiety” refers to a molecule capable of specifically binding a target or marker, including but not limited to, an antibody, antigen-binding fragment, aptamer, nucleic acid probe, receptor, ligand, lectin, affibody, peptide, or combinations thereof.

[0075] As used herein, the term “transfer characteristic curve” refers to a measurement of drain current as a function of gate voltage at a fixed drain-source voltage, revealing operating regimes of the transistor including subthreshold, linear, and saturation regimes.

[0076] As used herein, the term “subthreshold regime” refers to an operating region of a fieldeffect transistor where drain current increases exponentially with gate voltage, providing enhanced sensitivity to surface charge perturbations compared to linear or saturation regimes.

[0077] As used herein, the term “Debye length” refers to the characteristic length scale over which electrostatic effects persist in an ionic solution, which decreases with increasing ionic strength and increases with decreasing ionic strength.092012-0079-W001

[0078] As used herein, the term “Debye screening” refers to the shielding of electrostatic interactions between charged molecules and a sensing surface by counterions in an electrolyte solution, which limits the distance over which electrostatic coupling can occur.

[0079] As used herein, the term “extracellular vesicle” or “EV” refers to a membrane-bound particle released by cells that carries molecular cargo including proteins, nucleic acids, and / or lipids, which may be identified by surface markers including, but not limited to, CD63 and CD81.

[0080] As used herein, the term “supermere” refers to an extracellular nanoparticle that is distinct from exosomes and exomeres, which may be identified by surface markers including, but not limited to, HSPA13.

[0081] As used herein, the term “exomere” refers to a non-membranous extracellular nanoparticle that is smaller than exosomes and carries distinct molecular cargo.

[0082] As used herein, the term “biochip” refers to a device comprising a chip substrate with integrated components including inlets, outlets, microfluidic channels, buffer reservoirs, ion exchange membranes, and sensors configured for biosensing applications.

[0083] Field-effect transistor (FET) biosensor devices represent a class of sensing platforms that detect charged biomolecules through modulation of electrical characteristics at a semiconductor interface. These devices offer advantages including label-free detection, compatibility with semiconductor fabrication processes, and potential for miniaturization and integration into portable diagnostic systems. Field-effect transistor biosensors may be configured to detect a variety of target analytes and nanocarriers including, but not limited to, nucleic acids, proteins, extracellular vesicles, lipoproteins, viruses, and other nanocarriers of biomarkers.

[0084] Described herein are field-effect transistor (FET)-based biosensor platforms. In one aspect, a membrane-enhanced version of the FET biosensor platform is described in which an optional ion exchange membrane (IEM) is included that creates ion depletion near a sensing electrode to improve sensitivity by removing Debye screening and thus eliminating the need for pretreatment. In another aspect, a multi-marker nanocarrier detection, isolation, enrichment, and / or quantification biosensor platform is described that uses sequential or sandwich binding of a first marker, a second marker, and optionally a third marker, with charged reporter particles and FET signal that cannot be corrupted by interfering agents in untreated plasma. The charged reporter particles allow for accurate reporting of the number of nanocarriers. The disclosed multimarker nanocarrier detection, isolation, enrichment, and / or quantification devices and methods may be carried out with or without an ion exchange membrane and with or without ion depletion.

[0085] Described herein are biosensor systems, devices, and methods for detecting target analytes and biomolecules with enhanced sensitivity and selectivity. In various aspects, the092012-0079-W001

[0086] biosensor devices comprise a field-effect transistor (FET) comprising a gate terminal, a source terminal, and a drain terminal, and a sensing electrode electrically connected to the gate terminal of the FET, the sensing electrode configured to capture target biomolecules directly or indirectly. In some embodiments, the biosensor device further comprises a microfluidic channel positioned adjacent to the sensing electrode. In some embodiments, the biosensor device further comprises an ion exchange membrane (IEM) positioned within or adjacent to the microfluidic channel and one or more electrodes configured to apply an electric field across the IEM to generate an ion depletion zone proximate to the sensing electrode. In some embodiments, the target biomolecules comprise microRNA sequences, extracellular vesicles (EVs), supermeres, proteins, lipoproteins, exomeres, viruses, or combinations thereof. In some embodiments, detection is achieved using charged reporter particles associated with the target biomolecules. In some embodiments, the biosensor device is configured for multi-marker detection, isolation, enrichment, and / or quantification of nanocarriers based on co-localization of at least two distinct markers on the same nanocarrier.

[0087] In some embodiments, the disclosure provides methods and devices for isolating, detecting, or quantifying nanocarriers that co-express at least two distinct surface markers using a field-effect transistor readout. In certain embodiments, the methods use charged reporter particles and do not require ion depletion or an ion exchange membrane. In other embodiments, an ion exchange membrane is used to generate an ion depletion zone proximate to the sensing electrode, thereby enhancing electrostatic coupling and sensitivity during FET readout.

[0088] Field-Effect Transistor (FET) Biosensors

[0089] The present disclosure describes biosensor devices, systems, and methods comprising a field-effect transistor (FET). In some embodiments, the devices, systems, and methods may integrate ion depletion technology with FET sensing to address the limitations imposed by Debye screening. By reducing ionic strength in the region proximate to the sensing electrode, the effective Debye length may be increased, thereby enhancing electrostatic coupling between target biomolecules and the sensing interface. This approach enables detection of charged biomolecules with improved sensitivity and reproducibility compared to conventional field-effect transistor biosensors operated in physiological ionic strength conditions. The ion depletion approach may be implemented using ion exchange membranes positioned within microfluidic channels, where application of an electric field across the membrane generates a localized ion depletion zone near the sensing electrode. This configuration may provide a consistent low ionic strength environment during signal measurement, which may improve sensor reliability and092012-0079-W001

[0090] enable detection of target analytes at concentrations that would otherwise be undetectable due to Debye screening effects.

[0091] In other embodiments, the FET is used without membrane ion depletion. In these embodiments, the disclosed biosensor devices, systems, and methods may comprise one or more of: measurement in reduced-ionic-strength buffer, measurement after washing into a lower ionic-strength medium, measurement using charged reporters sufficiently close to a sensing electrode, or measurement in subthreshold regime with or without ion depletion.

[0092] Multi-Marker Nanocarrier Isolation and Quantification

[0093] In some embodiments, the disclosed biosensor devices, systems, and methods are configured for multi-marker detection of nanocarriers by capture through a first marker and detection or quantification through a second marker, optionally followed by cleavage and detection through a third marker. Since it is unlikely that a single nanocarrier from a healthy cell would display two overexpressed biomarkers, the multi-marker platform described herein allows for a selective assay of only nanocarriers from diseased cells. These disclosed multi-marker aspects may be practiced either with or without an I EM for ion depletion.

[0094] In one embodiment, multi-marker detection of nanocarriers may be practiced using a FET readout with charged reporter particles. In another embodiment, the reporter particles may be magnetic or non-magnetic silica nanoparticles. In various aspects, this multi-marker detection approach may be used for isolation, enrichment, detection, quantification, and / or normalization of diseased-cell nanocarriers.

[0095] In various aspects, the disclosure provides methods and devices for isolating, enriching, detecting, and / or quantifying nanocarriers based on co-localization of multiple markers on the same nanocarrier. This approach may be useful where a single marker is insufficiently selective because the marker is present on nanocarriers from both diseased and non-diseased cells.

[0096] In some embodiments, a sample comprising nanocarriers is contacted with a first capture reagent specific for a first marker, thereby capturing nanocarriers that express the first marker. In certain embodiments, the first capture reagent is associated with a bead, surface, substrate, electrode, or other solid support. In some embodiments, captured nanocarriers are then contacted with a second binding reagent specific for a second marker. Detection of the second marker on nanocarriers captured through the first marker identifies nanocarriers that co-localize the first marker and the second marker on the same nanocarrier.

[0097] In some embodiments, the second binding reagent is associated with a charged reporter particle, including a charged magnetic particle or charged non-magnetic particle. In certain092012-0079-W001

[0098] embodiments, the charged reporter particle is sufficiently charged and sufficientiy proximate to a sensing electrode to modulate an electrical characteristic of a field-effect transistor, thereby enabling FET-based detection or quantification of nanocarriers that co-express the first and second markers.

[0099] In some embodiments, the charged reporter particles comprise silica particles or magnetic particles functionalized with dense binding moieties, thereby providing avidity and reducing nonspecific signal. In some embodiments, one reporter particle binds to one nanocarrier. In some embodiments, nonspecifically associated reporter particles are removed by washing prior to measurement.

[0100] In certain optional embodiments, the nanocarriers are released, cleaved, dissociated, or otherwise separated from a first support after a first multi-marker measurement and then recaptured or re-probed using a third binding reagent specific for a third marker. In this manner, nanocarriers co-expressing first, second, and third markers may be isolated, detected, and / or quantified.

[0101] In some embodiments, the nanocarriers comprise extracellular vesicles. In some embodiments, the nanocarriers are diseased-cell-derived or disease-associated extracellular vesicles. In some embodiments, quantification of such nanocarriers is used to normalize subsequent analysis of cargo molecules, including, for example, nucleic acids and proteins.

[0102] In some embodiments, the multi-marker nanocarrier methods disclosed herein are performed without an ion exchange membrane and without ion depletion. In other embodiments, an ion exchange membrane is used to enhance sensitivity during FET measurement. Accordingly, the multi-marker nanocarrier methods may be practiced either with or without ion depletion enhancement. For example, in some embodiments, the multi-marker strategy shown in FIG. 14A is implemented as a standalone nanocarrier isolation and quantification workflow independent of ion depletion. In other embodiments, the same workflow is combined with ion depletion using an ion exchange membrane to increase sensitivity of FET readout. Thus, ion depletion may be used as an optional sensitivity enhancement in the multi-marker nanocarrier detection applications disclosed herein.

[0103] Biosensor Device Architecture

[0104] Referring to FIG. 1A, a schematic diagram illustrates an exemplary field-effect transistor coupled with a depletion module for biosensing applications as disclosed herein. The configuration comprises two primary functional blocks: a depletion module and a FET transducer.092012-0079-W001

[0105] The depletion module and the FET transducer may be arranged to operate in conjunction to enable detection of charged biomolecules with enhanced sensitivity.

[0106] In the exemplary embodiment shown in FIG. 1A, the depletion module is depicted on the left side of the diagram and includes multiple ion exchange membrane elements arranged within an enclosed housing. The depletion module has negative and positive terminals indicated at the top left and top right corners respectively. The membrane elements are shown as elongated structures with rounded ends, representing ion-selective membrane components that facilitate ion depletion when an electric field is applied across the terminals. The arrangement of the ion exchange membrane elements within the depletion module may enable selective transport of ions based on charge, thereby creating a localized region of reduced ionic strength.

[0107] With continued reference to FIG. 1A, the FET transducer is shown on the right side of the diagram and comprises a transistor package with multiple terminal pins extending from the bottom. The transistor may be configured to operate with a constant drain-source voltage (VDS) while the drain-source current (IDS) is measured. This configuration enables characterization of the transistor response to changes in gate potential induced by biomolecular binding events at the sensing interface.

[0108] A connection extends from the positive terminal of the depletion module to the gate terminal of the FET transducer. This connection passes through a switching element positioned at the output of the depletion module. Below the switching element, a variable capacitor symbol with an arrow indicates a sweep voltage applied to the gate, labeled as Sweep VG. This configuration allows the gate voltage to be swept while measuring the resulting drain current to obtain transfer characteristic curves. The transfer characteristic measurement mode may be employed to assess sensor response across different operating regimes of the transistor, including subthreshold, linear, and saturation regimes.

[0109] The circuit arrangement depicted in FIG. 1A enables the depletion module to reduce ionic strength in the sensing region near the FET gate, thereby extending the Debye length and enhancing electrostatic coupling between target biomolecules and the sensing electrode. A ground connection is shown at the bottom of the FET transducer, completing the circuit path for current measurement. The integration of the depletion module with the FET transducer may provide a platform for detecting charged biomolecules in samples that would otherwise exhibit Debye screening effects under physiological ionic strength conditions.

[0110] Referring to FIG. 1B-C, a top-down photograph illustrates an exemplary assembled biochip for biosensing applications as disclosed herein. The biochip comprises a chip substrate that serves as a base platform for the sensing components. A pair of buffer reservoirs are092012-0079-W001

[0111] positioned at opposite ends of the chip, appearing as cylindrical containers configured to hold buffer solutions during operation. An inlet is located on one side of the chip for introducing samples into the microfluidic system, while an outlet is positioned on the opposite side for fluid egress. Ion exchange membranes are positioned beneath the buffer reservoirs within a microfluidic channel structure. A plurality of sensors are arranged in a parallel configuration between the two buffer reservoirs, appearing as elongated gold electrodes with expanded contact regions at their ends. The sensors are positioned within the microfluidic channel to enable detection of target biomolecules. The assembled configuration demonstrates the integration of the ion exchange membranes with the sensing electrodes, enabling ion depletion near the sensor surfaces during operation to enhance detection sensitivity.

[0112] With continued reference to FIG. 1B and specifically referring to FIG. 1C, a schematic view illustrates a biochip 100. The biochip 100 includes a chip substrate 102 that provides structural support for the various components of the biochip 100. The chip substrate 102 may be fabricated from polycarbonate sheet material. Positioned on the chip substrate 102 are two buffer reservoirs 106 located at opposite ends of the biochip 100. The buffer reservoirs 106 are cylindrical structures configured to hold buffer solutions during operation. In some embodiments, the buffer reservoirs 106 may be 3D printed using, for example, a Stereolithography (SLA) 3D printer.

[0113] As further shown in FIG. 1C, an inlet 104 is positioned adjacent to one of the buffer reservoirs 106 and provides a pathway for introducing samples into the biochip 100. An outlet 112 is positioned adjacent to the other buffer reservoir 106 and provides a pathway for fluid to exit the biochip 100. A microfluidic channel extends between the inlet 104 and the outlet 112, providing a fluid pathway through the biochip 100. In certain nonlimiting exemplary embodiments, the microfluidic channel may have dimensions of about 3.5 cm in length, about 2 mm in width, and about 300 pm in height, corresponding to a total internal volume of approximately 21 pL. A plurality of sensors 110 are positioned in a central region of the biochip 100 between the two buffer reservoirs 106. The sensors 110 extend as elongated structures configured for detecting target biomolecules. The sensors 110 are positioned within the microfluidic channel to enable contact with sample fluids flowing through the biochip 100.

[0114] With continued reference to FIG. 1C, ion exchange membranes 108 are positioned beneath each of the buffer reservoirs 106 within the microfluidic channel structure. The ion exchange membranes 108 are configured to enable ion depletion when an electric field is applied across the buffer reservoirs 106, thereby reducing ionic strength in the region proximate to the sensors 110 to enhance detection sensitivity. The positioning of the ion exchange membranes092012-0079-W001

[0115] 108 beneath the buffer reservoirs 106 enables selective ion transport when a voltage is applied across electrodes positioned within the buffer reservoirs 106, creating a localized ion depletion zone in the microfluidic channel near the sensors 110. The spatial arrangement of the biochip 100 with the pair of buffer reservoirs 106 positioned at opposite ends of the microfluidic channel, the ion exchange membranes 108 positioned beneath the buffer reservoirs 106, and the plurality of sensors 110 positioned within the microfluidic channel between the buffer reservoirs 106 provides a configuration that enables controlled ion depletion during biosensing operations. This arrangement may facilitate the generation of a consistent low ionic strength environment proximate to the sensors 110 during signal measurement.

[0116] Referring to FIG. 2, an exemplary transfer characteristic curve illustrates drain current as a function of gate-source voltage for a field-effect transistor. The field-effect transistor comprises a gate terminal, a source terminal, and a drain terminal. In the transfer characteristic measurement, the drain current (ID) is recorded while sweeping the gate voltage (VG) at a fixed drain-source voltage (VDS). In some embodiments, the field-effect transistor may be operated at a drain-source bias (VDS) of about 0.05 V during transfer characteristic measurement. In some embodiments, the gate bias may be swept in a range of about -2 V to about +2 relative to reference during transfer characteristic measurement.

[0117] The transfer characteristic curve depicted in FIG. 2 reveals distinct operating regimes of the transistor. A subthreshold regime is shown on the left side of the curve where the drain current increases exponentially with gate voltage. A linear regime is shown where the drain current rises approximately linearly with gate voltage. A saturation regime is shown where the drain current plateaus due to pinch-off effects. The transition between these regimes is visible in the characteristic S-shaped curve when plotted on a logarithmic scale.

[0118] With continued reference to FIG. 2, the subthreshold regime provides enhanced sensitivity for biosensing applications. In the subthreshold regime, biomolecular binding events at the sensing electrode induce a shift in effective gate voltage. For negatively charged target biomolecules such as microRNA hybridizing to probes on the gate, this shift in effective gate voltage leads to an exponential change in drain current. This non-linear amplification in the subthreshold regime enhances the signal-to-noise ratio and improves the responsiveness of the device to low-abundance analytes. Operating the field-effect transistor in the subthreshold regime may maximize sensitivity to surface charge perturbations induced by biomolecular binding events.

[0119] As further shown in FIG. 2, an inset illustration depicts a schematic representation of a sensing surface with probe molecules attached to a substrate, showing the functionalized electrode configuration used in biosensing applications. The change in drain current (ΔID)092012-0079-W001

[0120] between curves in the subthreshold region indicates the sensor response to target analyte binding. The sensor response may be quantified by analyzing the shift in drain current (ΔID) calculated as (I0— ID) / I0, where I0represents the baseline drain current and IDrepresents the drain current after target analyte binding. The method may include extracting threshold voltage from the baseline transfer characteristics to establish a reference point for quantifying sensor response.

[0121] In various aspects, the field-effect transistor may comprise an n-type enhancement mode metal-oxide-semiconductor field-effect transistor (MOSFET). In some embodiments, the fieldeffect transistor may comprise two-dimensional semiconducting materials such as graphene, molybdenum disulfide (MoS2), or MXene. These two-dimensional semiconducting materials exhibit carrier mobility and surface-to-volume ratios that may enable sensitive modulation of channel conductance in response to charge perturbations at the gate interface. The measurement of the transfer characteristic curve by sweeping the gate voltage while maintaining a fixed drain-source voltage enables characterization of the transistor response across the subthreshold, linear, and saturation regimes, with the subthreshold regime providing the operating conditions for detecting low-abundance target analytes.

[0122] In some embodiments, the FET biosensor is operated without ion depletion. In certain embodiments, sensitivity is obtained by using charged reporter particles, by operating the FET in a subthreshold regime, by reducing ionic strength of the sample or wash buffer, by positioning reporter particles proximate to the sensing electrode, or by combinations thereof. In other embodiments, ion depletion provided by an ion exchange membrane is used in addition to one or more of the foregoing approaches.

[0123] Ion Exchange Membranes

[0124] In various aspects, ion exchange membranes may be integrated into biosensor devices to enhance detection sensitivity of target biomolecules. The ion exchange membrane may comprise a cation exchange membrane or an anion exchange membrane. In some embodiments, the cation exchange membrane may comprise sulphonate ion-exchange groups (R-SO3’) that enable selective transport of cations while rejecting anions. The cation exchange membrane may have sodium (Na+) as the ionic form counterion. In some embodiments, the anion exchange membrane may comprise quaternary ammonium (R-(CH3)3N+) ion-exchange groups that enable selective transport of anions while rejecting cations. The anion exchange membrane may have chloride (Cl-) as the ionic form counterion.

[0125] In some embodiments, the ion exchange membrane may have a thickness of about 300 pm. For example, the ion exchange membrane may have a thickness ranging from about 50 pm092012-0079-W001

[0126] to about 500 pm, about 100 pm to about 400 pm, or about 250 pm to about 350 pm. In certain embodiments, the ion exchange membrane may have a thickness ranging from about 75 pm to about 450 pm, about 100 pm to about 400 pm, about 150 pm to about 375 pm, about 200 pm to about 350 pm, or about 250 pm to about 325 pm. In some embodiments, the ion exchange membrane may have a thickness less than about 500 pm, less than about 400 pm, less than about 350 pm, or less than about 300 pm. In other embodiments, the ion exchange membrane may have a thickness greater than about 50 pm, greater than about 75 pm, greater than about 100 pm, or greater than about 150 pm. The ion exchange membrane may comprise a polyethylene (PE) basic binder on base. The ion exchange membrane may comprise polyester (PES) fitting fabrics. The ion exchange membrane may have a permselectivity greater than 90% measured at 0.5 / 0.1M KCI. In certain nonlimiting exemplary embodiments, the ion exchange membrane may be cut to a size of 3 mm and affixed to openings on the microfluidic channel.

[0127] During ion depletion operation, a DC voltage electric field may be applied across the ion exchange membrane. In some embodiments, applying the electric field may comprise applying a DC voltage in a range of about 5 V to about 200 V across the ion exchange membrane. For example, applying the electric field may comprise applying a DC voltage across the ion exchange membrane in a range of about 10 V to about 150 V, about 20 V to about 120 V, about 30 V to about 100 V, or about 40 V to about 80 V. In some embodiments, the DC voltage may be less than about 200 V, less than about 150 V, less than about 100 V, or less than about 75 V. In other embodiments, the DC voltage may be greater than about 5 V, greater than about 10 V, greater than about 20 V, or greater than about 30 V. In certain embodiments, applying the electric field may comprise applying a DC voltage of about 5 V, about 10 V, about 15 V, about 20 V, about 25 V, about 30 V, about 40 V, about 50 V, about 75 V, about 100 V, about 150 V, or about 200 V across the ion exchange membrane. In some embodiments, the DC voltage may be selected to achieve a desired electric field strength across the ion exchange membrane without causing dielectric breakdown, excessive Joule heating, or degradation of the membrane material. When the DC voltage is applied across a cation exchange membrane, cations pass through the membrane while anions are rejected due to the ion selectivity of the membrane. This selective ion transport leads to the formation of an ion depletion zone on one side of the membrane within the microfluidic channel.

[0128] In some embodiments, the ion depletion zone is configured to reduce local ionic strength from approximately 150 mM to below about 0.001 mM. Generating the ion depletion zone reduces local ionic strength from approximately 150 mM, which corresponds to physiological buffer conditions such as 1X PBS, to below about 0.001 mM. Depleting ions from the region proximate092012-0079-W001

[0129] to the sensing electrode reduces local ionic strength, thereby creating a deionized-water-like environment within the channel proximate to the sensing electrode. The reduction in local ionic strength results in a corresponding increase in the effective Debye length. In some embodiments, increasing the effective Debye length comprises increasing the Debye length to greater than about 100 nm. At physiological ionic strength of approximately 150 mM, the Debye length may be approximately 0.7 nm. When the local ionic strength is reduced to below 0.001 mM through ion depletion, the Debye length may increase to greater than 100 nm. This increase in Debye length enhances electrostatic coupling between target biomolecules captured on the sensing electrode and the gate interface of the field-effect transistor. The ion depletion operation provides a consistent ionic environment during signal measurement. By maintaining the region proximate to the sensing electrode at low ionic strength conditions, the ion depletion approach suppresses Debye screening effects that would otherwise limit detection sensitivity in physiological samples. The consistent low ionic strength environment may improve sensor reliability by reducing variability associated with ionic strength fluctuations in the sample.

[0130] Fabrication Methods

[0131] In various aspects, the sensing electrode is electrically connected to the gate terminal of the field-effect transistor and is configured to capture target biomolecules. In some embodiments, the sensing electrode may comprise a gold (Au) electrode. In certain aspects, the Au electrode may comprise a titanium adhesion layer and an Au layer deposited on the titanium (Ti) adhesion layer. The Au electrode may be fabricated using an Angstrom e-beam evaporation system. In certain nonlimiting exemplary embodiments, the fabrication process may comprise deposition of a 5 nm Ti adhesion layer followed by deposition of a 100 nm Au layer on the Ti adhesion layer. The Ti adhesion layer promotes adhesion between the Au layer and the underlying substrate material. In some embodiments, the electrode pattern may be formed on a thin plastic film supported on a polycarbonate sheet. Following gold deposition via e-beam evaporation, the thin plastic film may be peeled off to reveal the electrode pattern on the polycarbonate sheet. The fabricated electrode may be subsequently wire-bonded to the gate terminal of the field-effect transistor to establish the electrical connection between the sensing electrode and the gate terminal.

[0132] In various aspects, the sensing electrode may be functionalized with probe molecules configured to selectively bind the target biomolecules. The functionalization process may comprise multiple steps to prepare the gold electrode surface for probe attachment. The gold electrode may be cleaned by oxygen plasma treatment (e.g., about 10 minutes) prior to092012-0079-W001

[0133] functionalization. The oxygen plasma treatment removes organic contaminants from the gold electrode surface and activates the surface for subsequent chemical modification. Following oxygen plasma cleaning, the sensing electrode may be functionalized with a self-assembled monolayer of 11-mercaptoundecanoic acid (11-MUA) to form a carboxyl-terminated surface for probe attachment. The sensing electrode may be immersed in a solution of 11-MUA in ethanol for about 48 hours to form the self-assembled monolayer. The thiol group of the 11-MUA molecule binds to the gold surface through a gold-thiol bond, while the carboxylic acid group is presented at the outer surface of the monolayer. The 48-hour immersion period allows formation of a dense, well-ordered self-assembled monolayer on the gold electrode surface.

[0134] In some embodiments, the probe molecules may be covalently conjugated to the sensing electrode surface via EDC / NHS coupling chemistry. EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) and NHS (N-hydroxysuccinimide) coupling chemistry activates the carboxyl groups of the 11-MUA self-assembled monolayer for reaction with amine groups present on the probe molecules. The probe molecules may be applied at a concentration of, for example, 1 pM for conjugation to the sensing electrode surface. The probe molecules may comprise nucleic acid probes or antibodies, depending on the target biomolecules to be detected.

[0135] Following probe attachment, the sensing electrode surface may be passivated to reduce non-specific biomolecular adsorption. The sensing electrode surface may be passivated with PEG-thiol to reduce non-specific biomolecular adsorption. Alternatively, the sensing electrode surface may be passivated with BSA (bovine serum albumin) to reduce non-specific biomolecular adsorption. The passivation step blocks remaining reactive sites on the sensing electrode surface that are not occupied by probe molecules, thereby reducing background signal from non-specific binding of sample components during biosensing operations.

[0136] The plurality of sensors may comprise gold electrodes functionalized with probe molecules configured to selectively bind target biomolecules. The functionalization process described above may be applied to each of the plurality of sensors to prepare the sensors for detection of target biomolecules in sample fluids flowing through the microfluidic channel.

[0137] Targets Biomolecules

[0138] In various aspects, the probe molecules may comprise nucleic acid probes or antibodies, depending on the particular target biomolecules to be detected. In some embodiments, the probe molecules may comprise nucleic acid probes configured to hybridize with microRNA sequences as target analytes or biomolecules. The nucleic acid probes may be configured to hybridize with microRNA sequences selected from, for example, miR-21, miR-9, and / or miR-101-5p. As092012-0079-W001

[0139] disclosed herein, the microRNA miR-21 may have a sequence of 5 '-TAGCTTATCAGACTGATGTTGA-3 ' (SEQ ID NO: 1). As disclosed herein, the microRNA miR-9 may have a sequence of 5 ' -TCTTTGGTTATCTAGCTGTATG -3 ' (SEQ ID NO: 2). As disclosed herein, the microRNA miR-101-5p may have a sequence of 5 ' -CAGTTATC CAGTGCTGATGCT-3 ' (SEQ ID NO: 3). The nucleic acid probes may comprise DNA probes having sequences complementary to the target microRNA sequences to enable hybridization-based capture of the target microRNA molecules.

[0140] In other embodiments, the probe molecules may comprise antibodies configured to bind protein markers as target analytes or biomolecules. The antibodies may be configured to bind markers present on, for example, extracellular vesicles, supermeres, or other nanocarriers. In some exemplary aspects, the antibodies may comprise anti-CD63 antibodies configured to bind CD63 protein markers. In some exemplary aspects, the antibodies may comprise anti-CD81 antibodies configured to bind CD81 protein markers. In some exemplary aspects, the antibodies may comprise anti-HSPA13 antibodies configured to bind HSPA13 protein markers present on supermeres.

[0141] In various aspects, the target analyte or biomolecule may comprise one or more microRNA. The microRNA may comprise at least one of miR-21, miR-9, or miR-101-5p. In certain embodiments, the target analyte may comprise a single microRNA species, while in other embodiments the target analyte may comprise a plurality of microRNA species. In some embodiments, the biosensor may be configured to detect microRNA at a concentration in a range of about 10 fM to about 1 nM. For example, in certain embodiments, the biosensor may detect microRNA at a concentration in a range of about 25 fM to about 500 pM, about 50 fM to about 100 pM, about 100 fM to about 50 pM, or about 1 pM to about 10 pM. In certain embodiments, the biosensor may be capable of detecting microRNA at concentrations less than about 1 nM, less than about 500 pM, less than about 100 pM, or less than about 10 pM. In other embodiments, the biosensor may be capable of detecting microRNA at concentrations greater than about 10 fM, greater than about 25 fM, greater than about 50 fM, or greater than about 100 fM. The biosensor device may achieve a detection limit of femtomolar (fM) for microRNA targets. MicroRNA molecules carry negative charge due to the phosphate backbone of the nucleic acid structure, which enables detection through modulation of the field-effect transistor gate potential upon hybridization with complementary nucleic acid probes on the sensing electrode.

[0142] In various aspects, the target analyte or biomolecule may comprise extracellular vesicles. Extracellular vesicles (EVs) are nanocarrier membrane-bound particles released by cells that carry molecular cargo including proteins, nucleic acids, and lipids. In various aspects, the EVs092012-0079-W001

[0143] are weakly charged and require labeling with charged reporters. In some embodiments, these charged reporters are highly charged silica magnetic or non-magnetic nanoparticles, conjugated to antibodies for specific membrane proteins on the extracellular vesicles, such that only one reporter can bind to a single nanocarrier (e.g., see FIG. 14A). Their relatively large hydrodynamic radius also allows easy removal of non-specifically bound reporters by washing. Their size also allows for functionalization of dense antibodies such that high-affinity multi-valent binding (avidity) can be achieved. Another advantage of their size is that, in some embodiments, only one reporter can bind with one extracellular vesicle due to electrostatic repulsion and steric hindrance, allowing for accurate quantification of extracellular vesicles.

[0144] As parent diseased cells may overexpress certain proteins, their secreted extracellular vesicles also overexpress these proteins on their surface. However, since there are many more extracellular vesicles from healthy cells than diseased cells, a specific surface protein is found mostly on extracellular vesicles from healthy cells. Thus, to isolate or quantify only extracellular vesicles from diseased cells, a multi-marker strategy may be employed in various aspects disclosed herein, such as that shown in FIG. 14A. Because the chances of having two overexpressed surface proteins on the same extracellular vesicle is low for extracellular vesicles from healthy cells, different antibodies may be used to capture and report for different surface proteins. In various aspects, each reporter antibody is cleavable for release such that it will not interfere with the reporter signal of subsequent surface proteins on the extracellular vesicle.

[0145] In some exemplary aspects, the extracellular vesicles may comprise CD63-positive extracellular vesicles and / or CD81 -positive extracellular vesicles. CD63 and CD81 are tetraspanin surface proteins that serve as markers for extracellular vesicle identification and capture. In some embodiments, the biosensor may be configured to detect extracellular vesicles in a concentration range of about 105to about 109particles / mL. For example, in certain embodiments, the biosensor may detect extracellular vesicles in a concentration range of about 106to about 108particles / mL, about 5 * 105to about 5 x 108particles / mL, or about 107to about 109particles / mL. In some embodiments, the biosensor may detect extracellular vesicles in a concentration range of about 105to about 107particles / mL, about 106to about 108particles / mL, or about 107to about 108particles / mL. The biosensor device may achieve a detection limit of fM for exosomes and other nanocarriers. The size of extracellular vesicles may benefit from the extended Debye length achieved through ion depletion, as larger analytes may exhibit enhanced detection sensitivity under low ionic strength conditions.

[0146] In various aspects, the target analyte or biomolecule may comprise supermeres. Supermeres are extracellular nanoparticles that are distinct from exosomes and exomeres. In092012-0079-W001

[0147] certain embodiments, the target analyte may comprise supermeres, specifically HSPA13-positive supermeres. HSPA13 is a heat shock protein that serves as a marker for supermere identification. The probe molecules may comprise anti-HSPA13 antibodies for capture of HSPA13-positive supermeres on the sensing electrode.

[0148] In various aspects, the target analyte or biomolecule may comprise exomeres. Exomeres are non-membranous extracellular nanoparticles that are smaller than exosomes and carry distinct molecular cargo. The biosensor may be configured for detection of exomeres as target analytes using appropriate probe molecules configured for capture.

[0149] In various aspects, the target analyte or biomolecule may comprise lipoproteins. The target analyte may comprise lipoproteins, for example high-density lipoproteins (HDL). Lipoproteins are nanoparticles comprising lipids and proteins that transport cholesterol and other lipids in the bloodstream. The biosensor may be configured for detection of lipoproteins using antibodies or other probe molecules configured to bind lipoprotein surface components.

[0150] The charged biomolecules detectable by the biosensor devices disclosed herein may comprise at least one of microRNA, extracellular vesicles, supermeres, exomeres, lipoproteins, or viruses. In some embodiments, the biosensor may also be configured for detection of viruses as target analytes using appropriate probe molecules such as antibodies or nucleic acid probes. In some embodiments, the biosensor may also be configured for detection of nanoparticles as target analytes. The ion depletion approach described herein may enable detection of various charged nanoparticles and nanocarriers of biomarkers with enhanced sensitivity compared to conventional field-effect transistor biosensors operated under physiological ionic strength conditions.

[0151] In various aspects, for detection of weakly charged or uncharged target analytes such as antigens, extracellular vesicles, exomeres, or HDL, charged reporter particles may be employed to generate a detectable signal. Charged silica beads or magnetic beads attached to a detection antibody may be used as reporters. The reporter particles may be incubated with the captured target analytes to introduce charge proximate to the sensing electrode, thereby enabling detection through modulation of the field-effect transistor gate potential.

[0152] Biosensor Systems and Devices

[0153] Referring to FIG. 15, a block diagram illustrates an exemplary biosensor system 200. The biosensor system 200 comprises a biochip 202, a field-effect transistor 218, and a measurement circuit 222. In some embodiments, the biosensor system 200 may further comprise a voltage source 220 and an ion depletion module including an ion exchange membrane 214. The092012-0079-W001

[0154] biosensor system 200 integrates these components to enable sample introduction and electrical measurement for detection of target biomolecules, and optionally ion depletion for enhanced sensitivity. The biochip 202 includes several components arranged on a chip substrate 204. The chip substrate 204 provides structural support for the various components of the biochip 202. The biochip 202 comprises an inlet 206 and an outlet 208 positioned at opposite ends of the biochip 202. The inlet 206 provides a pathway for introducing samples into the biochip 202, while the outlet 208 provides a pathway for fluid to exit the biochip 202. A microfluidic channel 210 extends between the inlet 206 and the outlet 208, providing a pathway for fluid flow through the biochip 202. The microfluidic channel 210 enables transport of sample fluids from the inlet 206 to the outlet 208 while allowing contact between the sample and sensing components positioned within the microfluidic channel 210. A buffer reservoir 212 is positioned on the biochip 202. The biochip 202 may comprise a pair of buffer reservoirs 212 positioned at opposite ends of the microfluidic channel 210. The buffer reservoirs 212 are configured to hold buffer solutions during operation of the biosensor system 200.

[0155] As further shown in FIG. 15, in certain embodiments, an ion exchange membrane 214 may be positioned beneath the buffer reservoir 212. The ion exchange membrane 214 may comprise a cation exchange membrane positioned beneath each of the buffer reservoirs 212. The positioning of the ion exchange membrane 214 beneath the buffer reservoirs 212 enables selective ion transport when an electric field is applied across the ion exchange membrane 214. A plurality of sensors 216 are positioned within the microfluidic channel 210. The sensors 216 are configured for detection of target biomolecules in sample fluids flowing through the microfluidic channel 210. The sensors 216 may comprise gold electrodes functionalized with probe molecules.

[0156] With continued reference to FIG. 15, the field-effect transistor 218 is electrically connected to at least one of the plurality of sensors 216. The electrical connection between the sensors 216 and the field-effect transistor 218 enables modulation of the gate potential of the field-effect transistor 218 in response to biomolecular binding events at the sensors 216. In certain embodiments, the voltage source 220 is connected to the ion exchange membrane 214. In these optional embodiments, the voltage source 220 is configured to apply an electric field across the ion exchange membrane 214 to generate an ion depletion zone within the microfluidic channel 210 proximate to the sensors 216. The biosensor system 200 may further comprise platinum electrodes positioned within the pair of buffer reservoirs 212 and configured to receive a DC voltage in a range of, for example, about 5 V to about 200 from the voltage source 220. The092012-0079-W001

[0157] platinum electrodes positioned within the buffer reservoirs 212 enable application of the electric field across the ion exchange membrane 214 to induce ion depletion.

[0158] The measurement circuit 222 is connected to the field-effect transistor 218. The measurement circuit 222 is configured to measure drain current of the field-effect transistor 218 as a function of gate voltage. The measurement circuit 222 may record transfer characteristic curves by sweeping the gate voltage while maintaining a fixed drain-source voltage.

[0159] In some embodiments, during operation of the biosensor system 200, a sample is introduced through the inlet 206 and flows through the microfluidic channel 210 where target biomolecules are captured by the sensors 216. The voltage source 220 applies an electric field across the ion exchange membrane 214 to deplete ions from the region near the sensors 216, thereby reducing local ionic strength and increasing the effective Debye length. This ion depletion enhances electrostatic coupling between captured target biomolecules and the sensors 216. The measurement circuit 222 measures the electrical characteristics of the field-effect transistor 218 to detect and quantify the target biomolecules based on changes in drain current resulting from biomolecular binding events at the sensors 216.

[0160] Referring to FIG. 16, a block diagram illustrates an exemplary biosensor device 300. The biosensor device 300 comprises a field-effect transistor 302 and a sensing electrode 310 electrically connected to a gate terminal 304 of the field-effect transistor 302. In some embodiments, the biosensor device 300 further comprises a microfluidic channel 312 positioned adjacent to the sensing electrode 310. In some embodiments, the biosensor device 300 further comprises an ion exchange membrane 314 and an electrode pair 316 configured to generate an ion depletion zone proximate to the sensing electrode 310. In certain embodiments, the ion exchange membrane 314 and the electrode pair 316 provide an optional sensitivity-enhancement module. The biosensor device 300 may be configured for detecting charged biomolecules in a physiological sample. In some embodiments, the field-effect transistor 302 comprises a gate terminal 304, a source terminal 306, and a drain terminal 308. The gate terminal 304, the source terminal 306, and the drain terminal 308 provide the electrical connections for operating the fieldeffect transistor 302 in a biosensing configuration. The field-effect transistor 302 may comprise an n-type enhancement mode metal-oxide-semiconductor field-effect transistor. In some embodiments, the field-effect transistor 302 may comprise an organic field-effect transistor (OFET) as an alternative to the metal-oxide-semiconductor field-effect transistor configuration. The organic field-effect transistor configuration may provide flexibility in device fabrication and compatibility with different substrate materials.092012-0079-W001

[0161] With continued reference to FIG. 16, the sensing electrode 310 is electrically connected to the gate terminal 304 of the field-effect transistor 302. The electrical connection between the sensing electrode 310 and the gate terminal 304 enables modulation of the gate potential of the field-effect transistor 302 in response to biomolecular binding events at the sensing electrode 310. The sensing electrode 310 is configured to capture target biomolecules through probe molecules functionalized on the surface of the sensing electrode 310. The microfluidic channel 312 may be positioned adjacent to the sensing electrode 310. The positioning of the microfluidic channel 312 adjacent to the sensing electrode 310 enables contact between sample fluids flowing through the microfluidic channel 312 and the sensing electrode 310. The microfluidic channel 312 provides a pathway for introducing samples containing target analytes to the sensing electrode 310.

[0162] In some embodiments, the ion exchange membrane 314 may be positioned within the microfluidic channel 312. The positioning of the ion exchange membrane 314 within the microfluidic channel 312 enables selective ion transport when an electric field is applied across the ion exchange membrane 314. The ion exchange membrane 314 may comprise a cation exchange membrane or an anion exchange membrane. The electrode pair 316 is connected to the ion exchange membrane 314. The electrode pair 316 is configured to apply an electric field across the ion exchange membrane 314 to generate an ion depletion zone in a region of the microfluidic channel 312 proximate to the sensing electrode 310. When the electric field is applied across the ion exchange membrane 314 via the electrode pair 316, selective ion transport through the ion exchange membrane 314 creates a localized region of reduced ionic strength near the sensing electrode 310. The ion depletion zone generated proximate to the sensing electrode 310 reduces ionic strength and extends Debye length during detection. In certain embodiments, the physiological sample may comprise a buffer solution having an initial ionic strength of approximately 150 mM, and generating the ion depletion zone reduces the ionic strength to below 0.001 mM proximate to the sensing electrode 310. The reduction in ionic strength results in an increase in the effective Debye length. This extended Debye length enhances electrostatic coupling between target biomolecules captured on the sensing electrode 310 and the gate terminal 304 of the field-effect transistor 302, thereby improving detection sensitivity for charged biomolecules in physiological samples.

[0163] Methods of Operation

[0164] Referring to FIG. 14A, in some embodiments, a method for multi-marker nanocarrier quantification comprises: (a) contacting a sample comprising nanocarriers with a first binding reagent specific for a first marker; (b) capturing nanocarriers expressing the first marker on a092012-0079-W001

[0165] support; (c) contacting the captured nanocarriers with a second binding reagent specific for a second marker, wherein the second binding reagent is optionally associated with a charged reporter particle; (d) measuring an electrical characteristic of a field-effect transistor to detect or quantify nanocarriers that co-localize the first marker and the second marker on the same nanocarrier; and optionally, (e) releasing, cleaving, or dissociating the nanocarriers and recapturing or re-detecting the nanocarriers using a third binding reagent specific for a third marker. In some embodiments, the method is performed without ion depletion. In other embodiments, ion depletion is used during FET measurement by including an ion exchange membrane.

[0166] Referring to FIG. 17, a flowchart illustrates an exemplary method 400 for detecting a target analyte. The method 400 comprises a series of steps for detecting target analytes using a biosensor device disclosed herein. The method 400 begins with a step 402, where a biosensor device is provided. The biosensor device comprises a field-effect transistor having a sensing electrode electrically connected to a gate terminal of the field-effect transistor. In some embodiments, the biosensor device further comprises a microfluidic channel positioned adjacent to the sensing electrode. In some embodiments, the biosensor device further comprises an ion exchange membrane positioned within or adjacent to the microfluidic channel. The sensing electrode may be functionalized with probe molecules configured to selectively bind the target analyte. The biosensor device provided in the step 402 may comprise the biosensor device 300 described previously with reference to FIG. 16, or the biosensor system 200 described previously with reference to FIG. 15.

[0167] With continued reference to FIG. 17, the method 400 proceeds to a step 404, where a sample containing the target analyte is introduced into the microfluidic channel. Introducing the sample into the microfluidic channel may comprise introducing the sample through the inlet 104 of the biochip 100 with reference to FIG. 1C. The sample may comprise a physiological sample such as a buffer solution having an initial ionic strength of approximately 150 mM. The sample may contain target analytes including, but not limited to, microRNA, extracellular vesicles, supermeres, exomeres, lipoproteins, viruses, or other charged biomolecules. Following the introduction of the sample, the method 400 moves to a step 406, where the target analyte is captured on the sensing electrode. Capturing the target analyte on the sensing electrode may comprise binding of the target analyte to probe molecules functionalized on the sensing electrode surface. For nucleic acid target analytes such as microRNA, capturing may comprise hybridization between the target microRNA sequences and complementary nucleic acid probes on the sensing electrode. For protein or nanoparticle target analytes such as extracellular092012-0079-W001

[0168] vesicles or supermeres, capturing may comprise antibody-antigen binding between the target analyte and antibody probes on the sensing electrode.

[0169] As further shown in FIG. 17, in certain embodiments, the method 400 further comprises applying an electric field across the ion exchange membrane to generate an ion depletion zone proximate to the sensing electrode. Applying the electric field may comprise applying a DC voltage in a range of about 5 V to about 200 V across the ion exchange membrane. The ion depletion zone reduces local ionic strength, thereby increasing the effective Debye length. The extended Debye length enhances electrostatic coupling between the captured target analyte and the sensing electrode. In some embodiments, the method 400 may further comprise incubating the sample on the sensing electrode for a period of about 30 to about 60 minutes prior to applying an electric field in step 408. The incubation period allows target analyte molecules in the sample to diffuse to the sensing electrode surface and bind to the probe molecules. The incubation period may provide sufficient time for target analyte capture while maintaining practical assay duration for diagnostic applications. In other embodiments, the methods described herein are performed without an ion exchange membrane and without ion depletion.

[0170] The method 400 concludes with a step 410, where an electrical characteristic of the fieldeffect transistor is measured to detect the target analyte. Measuring the electrical characteristic may comprise measuring a transfer characteristic curve by sweeping a gate voltage while maintaining a fixed drain-source voltage. The field-effect transistor may be operated in a subthreshold regime to maximize sensitivity to surface charge perturbations induced by biomolecular binding events. The sensor response may be quantified by analyzing the shift in drain current (ΔID) between the baseline measurement and the measurement following target analyte capture and ion depletion.

[0171] The sequential arrangement of steps 402-410 in the method 400 provides a structured protocol for detecting target analytes using ion depletion to enhance electrostatic coupling between the target biomolecules and the sensing electrode. The method 400 may enable detection of target analytes at femtomolar concentrations that would be undetectable using conventional field-effect transistor biosensors operated under physiological ionic strength conditions.

[0172] Referring to FIG. 18, a flowchart illustrates an exemplary method 500 for enhancing sensitivity of a field-effect transistor biosensor. The method 500 comprises a series of steps for improving detection sensitivity through ion depletion, which increases the effective Debye length and enhances electrostatic coupling between target biomolecules and the sensing electrode. The method 500 begins with a step 502, where a field-effect transistor biosensor having a sensing092012-0079-W001

[0173] electrode functionalized with probe molecules for capturing target biomolecules is provided. The field-effect transistor biosensor may comprise the biosensor device 300 described previously with reference to FIG. 16, or the biosensor system 200 described previously with reference to FIG. 15. The sensing electrode may be functionalized with probe molecules comprising nucleic acid probes configured to hybridize with microRNA sequences or antibodies configured to bind protein markers. The probe molecules are configured to selectively bind target biomolecules present in sample fluids introduced to the biosensor.

[0174] With continued reference to FIG. 18, the method 500 proceeds to a step 504, where an ion exchange membrane is positioned within a microfluidic channel adjacent to the sensing electrode. The ion exchange membrane may comprise a cation exchange membrane or an anion exchange membrane. The positioning of the ion exchange membrane within the microfluidic channel adjacent to the sensing electrode enables selective ion transport when an electric field is applied, thereby creating a localized region of reduced ionic strength near the sensing electrode. The microfluidic channel provides a pathway for sample fluids to contact the sensing electrode while enabling ion depletion through the ion exchange membrane.

[0175] Following positioning of the ion exchange membrane, the method 500 moves to a step 506, where a sample is introduced into the microfluidic channel. The sample may comprise a physiological sample containing target biomolecules such as, for example, microRNA, extracellular vesicles, supermeres, exomeres, lipoproteins, and / or viruses. In some embodiments, the sample may have an initial ionic strength of approximately 150 mM corresponding to physiological buffer conditions. Introducing the sample into the microfluidic channel enables contact between the target biomolecules and the probe molecules on the sensing electrode for target capture.

[0176] As further shown in FIG. 18, the method 500 then continues to a step 508, where an electric field is applied across the ion exchange membrane to deplete ions from a region proximate to the sensing electrode, thereby increasing an effective Debye length and enhancing electrostatic coupling between the target biomolecules and the sensing electrode. The ion depletion achieved through the step 508 enhances electrostatic coupling between the target biomolecules captured on the sensing electrode and the gate interface of the field-effect transistor. This enhanced electrostatic coupling results in measurable changes in drain current at target analyte concentrations that would be undetectable under physiological ionic strength conditions due to Debye screening effects.

[0177] The sequential arrangement of steps 502-508 in the method 500 provides a structured approach for enhancing the detection sensitivity of field-effect transistor biosensors through ion092012-0079-W001

[0178] depletion. The method 500 may enable detection of target biomolecules at femtomolar concentrations, representing an improvement of four to five orders of magnitude compared to conventional field-effect transistor biosensors operated under physiological ionic strength conditions.

[0179] Referring to FIG. 19, a flowchart illustrates an exemplary method 600 for detecting a target analyte using a biosensor device. The method 600 comprises a series of steps that incorporate transfer characteristic measurement and subthreshold regime operation to maximize detection sensitivity for target analytes. The method 600 begins with a step 602, where a biosensor device is provided. The biosensor device comprises a field-effect transistor, a sensing electrode electrically connected to a gate terminal of the field-effect transistor, a microfluidic channel positioned adjacent to the sensing electrode, and an ion exchange membrane positioned within the microfluidic channel. The biosensor device provided in the step 602 may comprise the biosensor device 300 described previously with reference to FIG. 16, or the biosensor system 200 described previously with reference to FIG. 15. The sensing electrode may be functionalized with probe molecules configured to selectively bind target analytes.

[0180] With continued reference to FIG. 19, the method 600 proceeds to a step 604, where a sample containing the target analyte is introduced into the microfluidic channel. Following the introduction of the sample, the method 600 moves to a step 606, where the target analyte is captured on the sensing electrode. Capturing the target analyte on the sensing electrode may comprise binding of the target analyte to probe molecules functionalized on the sensing electrode surface. The method 600 may include incubating the sample on the sensing electrode for a period of time to allow target analyte capture prior to subsequent steps. The method 600 then continues to a step 608, where an electric field is applied across the ion exchange membrane to generate an ion depletion zone proximate to the sensing electrode. In step 610, a transfer characteristic curve is measured by sweeping a gate voltage while maintaining a fixed drain-source voltage. The transfer characteristic measurement involves recording drain current (ID) as a function of gate voltage (VG) at a constant drain-source voltage (VDS). In some embodiments, the drain-source voltage may be maintained at about 0.05 V during the transfer characteristic measurement, and the gate voltage may be swept in a range of about -2 V to about +2 V relative to reference during the transfer characteristic measurement. Measuring the transfer characteristic curve by sweeping the gate voltage while maintaining the fixed drain-source voltage enables characterization of the transistor response across different operating regimes, including the subthreshold regime, the linear regime, and the saturation regime.092012-0079-W001

[0181] The method 600 concludes with a step 612, where the field-effect transistor is operated in a subthreshold regime to detect the target analyte. Operating the field-effect transistor biosensor in the subthreshold regime maximizes sensitivity to surface charge perturbations induced by biomolecular binding events at the sensing electrode. In the subthreshold regime, the drain current increases exponentially with gate voltage, such that small shifts in effective gate potential induced by charged target biomolecules result in exponential changes in drain current. This nonlinear amplification in the subthreshold regime enhances the signal-to-noise ratio and improves the responsiveness of the biosensor device to low-abundance target analytes. The subthreshold regime operation described in the step 612 provides enhanced sensitivity compared to operation in the linear or saturation regimes. When negatively charged target biomolecules such as microRNA hybridize to probes on the sensing electrode, the accumulated charge induces a shift in the effective gate voltage. In the subthreshold regime, this shift in effective gate voltage produces an exponential change in drain current, thereby amplifying the sensor response to biomolecular binding events. The combination of ion depletion to extend the Debye length and subthreshold regime operation to maximize sensitivity to surface charge perturbations enables detection of target analytes at femtomolar concentrations.

[0182] The sequential arrangement of steps 602-612 in the method 600 provides a structured protocol for detecting target analytes with enhanced sensitivity through the combination of ion depletion and optimized electrical measurement techniques. The method 600 may enable quantitative detection of charged biomolecules in physiological samples at concentrations that would be undetectable using conventional field-effect transistor biosensors operated under physiological ionic strength conditions without subthreshold regime optimization.

[0183] Referring to FIG. 20, a flowchart illustrates an exemplary method 700 for enhancing sensitivity of a field-effect transistor biosensor. The method 700 comprises a series of steps that integrate ion depletion with optimized electrical measurement techniques, including transfer characteristic measurement in the subthreshold regime to maximize detection sensitivity for target biomolecules. The method 700 begins with a step 702, where a field-effect transistor biosensor having a sensing electrode functionalized with probe molecules is provided. The field-effect transistor biosensor may comprise the biosensor device 300 described previously with reference to FIG. 16, or the biosensor system 200 described previously with reference to FIG. 15. The sensing electrode may be functionalized with probe molecules comprising nucleic acid probes configured to hybridize with microRNA sequences or antibodies configured to bind protein markers. The probe molecules are configured to selectively bind target biomolecules present in092012-0079-W001

[0184] sample fluids introduced to the biosensor. The functionalization of the sensing electrode with probe molecules enables selective capture of target biomolecules from complex sample matrices.

[0185] With continued reference to FIG. 20, the method 700 proceeds to a step 704, where an ion exchange membrane is positioned within a microfluidic channel adjacent to the sensing electrode. The ion exchange membrane may comprise a cation exchange membrane or an anion exchange membrane. The positioning of the ion exchange membrane within the microfluidic channel adjacent to the sensing electrode enables selective ion transport when an electric field is applied across the ion exchange membrane. The spatial relationship between the ion exchange membrane and the sensing electrode determines the location of the ion depletion zone that forms during operation, with the ion depletion zone forming in the region of the microfluidic channel proximate to the sensing electrode.

[0186] Following positioning of the ion exchange membrane, the method 700 moves to a step 706, where a sample is introduced into the microfluidic channel. Introducing the sample into the microfluidic channel enables contact between the target biomolecules in the sample and the probe molecules on the sensing electrode for target capture. The method 700 may also include incubating the sample on the sensing electrode for a period of time following introduction of the sample to allow target biomolecules to diffuse to the sensing electrode surface and bind to the probe molecules.

[0187] As further shown in FIG. 20, the method 700 then continues to a step 708, where an electric field is applied across the ion exchange membrane to deplete ions from a region proximate to the sensing electrode, thereby increasing an effective Debye length. When the electric field is applied across the ion exchange membrane, selective ion transport through the membrane creates a localized ion depletion zone in the microfluidic channel near the sensing electrode. The increase in effective Debye length achieved through the step 708 enhances electrostatic coupling between target biomolecules captured on the sensing electrode and the gate interface of the fieldeffect transistor.

[0188] Under physiological ionic strength conditions prior to ion depletion, the Debye length of approximately 0.7 nm limits the distance over which electrostatic interactions between charged target biomolecules and the sensing electrode can occur. The short Debye length under physiological conditions results in Debye screening, where counterions in the electrolyte solution shield the charge associated with captured target biomolecules before the charge can modulate the gate potential of the field-effect transistor. When ion depletion reduces the local ionic strength to below 0.001 mM, the extended Debye length of greater than 100 nm enables the charge associated with captured target biomolecules to modulate the gate potential over distances that092012-0079-W001

[0189] encompass the bound target molecules, thereby producing measurable changes in the electrical characteristics of the field-effect transistor.

[0190] With continued reference to FIG. 20, the method 700 concludes with a step 710, where a transfer characteristic curve is measured in a subthreshold regime to maximize sensitivity. Measuring the transfer characteristic curve comprises recording drain current (ID) as a function of gate voltage (VG) while maintaining a fixed drain-source voltage (VDS)- The subthreshold regime operation specified in the step 710 provides enhanced sensitivity to surface charge perturbations compared to operation in the linear or saturation regimes of the field-effect transistor. In the subthreshold regime, the drain current increases exponentially with gate voltage, such that small shifts in effective gate potential induced by charged target biomolecules result in exponential changes in drain current. This non-linear amplification characteristic of the subthreshold regime enhances the signal-to-noise ratio and improves the responsiveness of the biosensor to low-abundance target analytes. When negatively charged target biomolecules such as microRNA hybridize to complementary probes on the sensing electrode, the accumulated negative charge induces a shift in the effective gate voltage. In the subthreshold regime, this shift in effective gate voltage produces an exponential change in drain current, thereby amplifying the sensor response to biomolecular binding events.

[0191] The integration of ion depletion with subthreshold regime measurement in the method 700 provides a synergistic approach for enhancing detection sensitivity. The ion depletion achieved through the step 708 extends the Debye length to enable electrostatic coupling between captured target biomolecules and the sensing electrode over distances that would otherwise be screened under physiological ionic strength conditions. The subthreshold regime measurement specified in the step 710 maximizes the electrical response of the field-effect transistor to the surface charge perturbations enabled by the extended Debye length. The combination of these two sensitivity enhancement mechanisms enables detection of target analytes at femtomolar concentrations, representing an improvement of at least four to five orders of magnitude compared to conventional field-effect transistor biosensors operated under physiological ionic strength conditions without subthreshold regime optimization.

[0192] The sequential arrangement of steps 702-710 in the method 700 provides a structured protocol for enhancing the detection sensitivity of field-effect transistor biosensors through the integration of ion depletion and optimized electrical measurement techniques. The method 700 may enable quantitative detection of charged biomolecules including, but not limited to, microRNA, extracellular vesicles, supermeres, exomeres, lipoproteins, and / or viruses in physiological samples at concentrations that would be undetectable using conventional field-092012-0079-W001

[0193] effect transistor biosensors. The consistent low ionic strength environment provided by the ion depletion approach may also improve measurement reproducibility by eliminating variability associated with ionic strength fluctuations in physiological samples, thereby enabling robust calibration and reliable quantification of target analyte concentrations.

[0194] Described herein are biosensor systems, devices, compositions, and methods for detecting, isolating, enriching, and / or quantifying target biomolecules and nanocarriers using field-effect transistor (FET) sensing. In various aspects, the disclosure provides FET-based biosensor devices comprising a field-effect transistor having a gate terminal, a source terminal, and a drain terminal, and a sensing electrode electrically connected to the gate terminal and configured to capture target analytes directly or indirectly.

[0195] In some embodiments, the target analytes comprise nucleic acids, proteins, extracellular vesicles (EVs), exomeres, supermeres, lipoproteins, viruses, or combinations thereof. In some embodiments, weakly charged or uncharged target analytes are detected using charged reporter particles, including charged magnetic particles or charged non-magnetic particles, such as silica particles, associated with a binding moiety specific for the target analyte.

[0196] In some embodiments, the disclosure provides methods and devices for multi-marker detection, isolation, enrichment, and / or quantification of nanocarriers. In certain embodiments, a first binding moiety captures nanocarriers having a first surface marker, and a second binding moiety detects or reports nanocarriers having a second surface marker on the same nanocarrier, thereby identifying nanocarriers that co-express at least two distinct markers. In some embodiments, the method further comprises releasing or dissociating nanocarriers from a first capture reagent and re-capturing or re-detecting the nanocarriers using a third binding moiety specific for a third marker, thereby identifying nanocarriers that co-express three distinct markers.

[0197] In some embodiments, the disclosure provides methods for quantifying diseased-cell-derived nanocarriers by selecting nanocarriers that co-localize at least two overexpressed markers on the same nanocarrier. In certain embodiments, the nanocarriers comprise extracellular vesicles. In certain embodiments, the quantified nanocarriers are subsequently lysed or otherwise processed for analysis of cargo molecules, including nucleic acids, proteins, lipids, or combinations thereof. In some embodiments, nanocarrier quantification is used to normalize cargo measurements.

[0198] In some embodiments, the disclosure provides FET biosensor devices and methods in which a charged reporter particle is positioned sufficiently proximate to the sensing electrode to modulate an electrical characteristic of the FET. In certain embodiments, the electrical characteristic comprises drain current, threshold voltage, transconductance, a transfer092012-0079-W001

[0199] characteristic curve, or a shift in an effective gate potential. In some embodiments, the FET is operated in a subthreshold regime.

[0200] In some embodiments, the disclosure further provides an optional ion depletion module for enhancing sensitivity of the FET biosensors disclosed herein. For example, in certain embodiments, the biosensor device further comprises a microfluidic channel and an ion exchange membrane (IEM) positioned within or adjacent to the microfluidic channel, and one or more electrodes configured to apply an electric field across the IEM to generate an ion depletion zone proximate to the sensing electrode. In certain embodiments, the ion depletion zone reduces local ionic strength and increases an effective Debye length, thereby enhancing electrostatic coupling between captured target analytes or charged reporter particles and the sensing interface.

[0201] In some embodiments, the multi-marker nanocarrier detection, isolation, enrichment, and / or quantification methods are carried out without an ion exchange membrane. In other embodiments, the ion exchange membrane is used to enhance sensitivity during FET readout. In various aspects, the ion exchange membrane is an optional enhancement feature in all disclosed devices and methods.

[0202] One embodiment described herein is a biosensor device, comprising: a field-effect transistor (FET) comprising a gate terminal, a source terminal, and a drain terminal; and a sensing electrode electrically connected to the gate terminal of the FET, the sensing electrode configured to capture a target analyte directly or indirectly; wherein the biosensor device is configured to detect the target analyte based on a change in an electrical characteristic of the FET. In one aspect, the FET comprises an n-type enhancement mode metal-oxide-semiconductor FET (MOSFET). In another aspect, the sensing electrode comprises a gold electrode. In another aspect, the gold electrode comprises a titanium adhesion layer and a gold layer deposited on the titanium adhesion layer. In another aspect, the target analyte comprises a nanocarrier. In another aspect, the nanocarrier comprises an extracellular vesicle, exomere, supermere, lipoprotein, virus, or combinations thereof. In another aspect, the sensing electrode is configured to capture the target analyte using a first binding moiety specific for a first marker. In another aspect, the biosensor device is configured to detect the target analyte using a second binding moiety specific for a second marker on the same target analyte. In another aspect, the target analyte is a nanocarrier that co-localizes the first marker and the second marker. In another aspect, the second binding moiety is associated with a charged reporter particle. In another aspect, the charged reporter particle comprises a magnetic particle or a non-magnetic silica particle. In another aspect, the charged reporter particle is configured to modulate the electrical characteristic of the FET when positioned proximate to the sensing electrode to quantify the target analyte. In092012-0079-W001

[0203] another aspect, the biosensor device is configured to detect the target analyte using a third binding moiety specific for a third marker on the same target analyte. In another aspect, the electrical characteristic comprises one or more of drain current, threshold voltage, transconductance, or a transfer characteristic curve. In another aspect, the FET is operated in a subthreshold regime. In another aspect, the biosensor device further comprises a microfluidic channel positioned adjacent to the sensing electrode. In another aspect, the biosensor device further comprises an ion exchange membrane positioned within or adjacent to the microfluidic channel. In another aspect, the biosensor device further comprises one or more electrodes configured to apply an electric field across the ion exchange membrane to generate an ion depletion zone proximate to the sensing electrode. In another aspect, the sensing electrode is functionalized with probe molecules at a high density to selectively bind the target analyte with high affinity. In another aspect, the probe molecules comprise one or more antibodies or nucleic acid probes. In another aspect, the target analyte comprises microRNA sequences and the nucleic acid probes are configured to hybridize with the microRNA sequences.

[0204] Another embodiment described herein is a biosensor device, comprising: a field-effect transistor (FET) comprising a gate terminal, a source terminal, and a drain terminal; a sensing electrode electrically connected to the gate terminal of the FET, the sensing electrode configured to capture target biomolecules; a microfluidic channel positioned adjacent to the sensing electrode; an ion exchange membrane (IEM) positioned within the microfluidic channel; and a pair of electrodes configured to apply an electric field across the IEM to generate an ion depletion zone in a region of the microfluidic channel proximate to the sensing electrode. In one aspect, the IEM comprises a cation exchange membrane. In another aspect, the cation exchange membrane comprises sulphonate ion-exchange groups. In another aspect, the IEM comprises an anion exchange membrane. In another aspect, the biosensor device further comprises a pair of buffer reservoirs positioned at opposite ends of the microfluidic channel, wherein the IEM is positioned beneath at least one of the buffer reservoirs. In another aspect, the pair of electrodes comprises platinum electrodes positioned within the buffer reservoirs. In another aspect, the ion depletion zone is configured to reduce local ionic strength from about 150 mM to below about 0.001 mM.

[0205] Another embodiment described herein is a method for detecting or quantifying target nanocarriers, the method comprising: contacting a sample comprising nanocarriers with a first binding reagent specific for a first marker; capturing target nanocarriers expressing the first marker; contacting the captured target nanocarriers with a second binding reagent specific for a second marker; and measuring an electrical characteristic of a field-effect transistor (FET) to092012-0079-W001

[0206] detect or quantify target nanocarriers that co-localize the first marker and the second marker on the same nanocarrier. In one aspect, the second binding reagent is associated with a charged reporter particle. In another aspect, the charged reporter particle comprises a magnetic particle or a non-magnetic silica particle. In another aspect, the method further comprises washing to remove nonspecifically associated reporter particles prior to measuring the electrical characteristic. In another aspect, the nanocarriers comprise extracellular vesicles. In another aspect, measuring the electrical characteristic comprises measuring drain current as a function of gate voltage. In another aspect, the FET is operated in a subthreshold regime. In another aspect, the method further comprises releasing, cleaving, or dissociating the nanocarriers after detecting the first marker and the second marker, and re-capturing or re-detecting the nanocarriers using a third binding reagent specific for a third marker. In another aspect, the method further comprises lysing the detected or quantified nanocarriers and measuring one or more cargo molecules. In another aspect, the quantified nanocarriers are used to normalize the one or more cargo molecules. In another aspect, the method further comprises generating an ion depletion zone proximate to a sensing electrode by applying an electric field across an ion exchange membrane, wherein the sensing electrode is electrically connected to a gate terminal of the FET.

[0207] Another embodiment described herein is a method for detecting a target analyte, the method comprising: providing a biosensor device comprising a field-effect transistor (FET) having a sensing electrode electrically connected to a gate terminal of the FET; introducing a sample containing the target analyte into the biosensor device; capturing the target analyte on the sensing electrode; and measuring an electrical characteristic of the FET to detect the target analyte. In one aspect, the target analyte comprises a microRNA. In another aspect, the microRNA comprises at least one of miR-21, miR-9, or miR-101-5p. In another aspect, the target analyte comprises a nanocarrier. In another aspect, the nanocarrier comprises extracellular vesicles. In another aspect, the extracellular vesicles are detected using one or more charged reporter particles. In another aspect, the extracellular vesicles comprise surface proteins comprising CD63, CD81, or a combination thereof. In another aspect, the surface proteins of the extracellular vesicles comprise disease-associated protein biomarkers. In another aspect, measuring the electrical characteristic of the FET comprises measuring a transfer characteristic curve by sweeping a gate voltage while maintaining a fixed drain-source voltage. In another aspect, measuring the transfer characteristic curve comprises operating the FET in a subthreshold regime. In another aspect, the biosensor device further comprises a microfluidic channel positioned adjacent to the sensing electrode, and an ion exchange membrane (IEM) positioned092012-0079-W001

[0208] within or adjacent to the microfluidic channel. In another aspect, the method further comprises applying an electric field across the IEM to generate an ion depletion zone proximate to the sensing electrode. In another aspect, applying the electric field comprises applying a DC voltage of about 5 V to about 200 V across the IEM. In another aspect, the method further comprises incubating the sample on the sensing electrode for a period of about 30 minutes to about 60 minutes prior to applying the electric field. In another aspect, generating the ion depletion zone reduces local ionic strength from about 150 mM to below about 0.001 mM, thereby increasing an effective Debye length to greater than about 100 nm.

[0209] Another embodiment described herein is a biosensor system, comprising: a biochip comprising a chip substrate, an inlet, an outlet, and a plurality of sensors; a field-effect transistor (FET) electrically connected to at least one of the plurality of sensors; and a measurement circuit configured to measure drain current of the FET as a function of gate voltage. In one aspect, the biochip further comprises a microfluidic channel extending between the inlet and the outlet, at least one buffer reservoir, and an ion exchange membrane (IEM) positioned beneath the at least one buffer reservoir, the plurality of sensors being positioned within the microfluidic channel. In another aspect, the biosensor system further comprises a voltage source configured to apply an electric field across the IEM to generate an ion depletion zone within the microfluidic channel. In another aspect, the biochip comprises a pair of buffer reservoirs positioned at opposite ends of the microfluidic channel, and wherein the IEM comprises a cation exchange membrane or an anion exchange membrane positioned beneath each of the buffer reservoirs. In another aspect, the biosensor system further comprises platinum electrodes positioned within the pair of buffer reservoirs and configured to receive a DC voltage of about 5 V to about 200 V from a voltage source. In another aspect, the plurality of sensors comprises gold electrodes functionalized with probe molecules configured to selectively bind target biomolecules. In another aspect, the probe molecules comprise at least one of nucleic acid probes or antibodies. In another aspect, the measurement circuit is configured to operate the FET in a subthreshold regime to maximize sensitivity to surface charge perturbations induced by biomolecular binding events.

[0210] Another embodiment described herein is a method for enhancing sensitivity of a fieldeffect transistor (FET) biosensor, the method comprising: providing a FET biosensor having a sensing electrode functionalized with probe molecules for capturing target biomolecules; positioning an ion exchange membrane (IEM) within a microfluidic channel adjacent to the sensing electrode of the FET biosensor; introducing a sample into the microfluidic channel; and applying an electric field across the IEM to deplete ions from a region proximate to the sensing electrode, thereby increasing an effective Debye length and enhancing electrostatic coupling092012-0079-W001

[0211] between the target biomolecules and the sensing electrode. In one aspect, applying the electric field comprises applying a DC voltage of about 5 V to about 200 V across the IEM. In another aspect, depleting ions from the region proximate to the sensing electrode reduces local ionic strength from about 150 mM to below about 0.001 mM. In another aspect, the effective Debye length is increased to greater than about 100 nm. In another aspect, the probe molecules comprise at least one of nucleic acid probes configured to hybridize with target microRNA sequences or antibodies configured to bind target protein markers. In another aspect, the method further comprises measuring a transfer characteristic curve of the FET biosensor by sweeping a gate voltage while maintaining a fixed drain-source voltage, wherein the FET biosensor is operated in a subthreshold regime to maximize sensitivity to surface charge perturbations.

[0212] Another embodiment described herein is the use of a biosensor device for detecting target biomolecules in a physiological sample, the biosensor device comprising a field-effect transistor (FET) having a sensing electrode, a microfluidic channel, and an ion exchange membrane (IEM), wherein an electric field is applied across the IEM to generate an ion depletion zone proximate to the sensing electrode to reduce ionic strength and extend Debye length during detection. In one aspect, the target biomolecules are charged and comprise at least one of microRNA, extracellular vesicles (EVs), supermeres, exomeres, lipoproteins, proteins, or viruses.

[0213] It will be apparent to one of ordinary skill in the relevant art that suitable modifications and adaptations to the compositions, formulations, methods, processes, and applications described herein can be made without departing from the scope of any embodiments or aspects thereof. The compositions and methods provided are exemplary and are not intended to limit the scope of any of the specified embodiments. All of the various embodiments, aspects, and options disclosed herein can be combined in any variations or iterations. The scope of the compositions, formulations, methods, and processes described herein include all actual or potential combinations of embodiments, aspects, options, examples, and preferences herein described. The exemplary compositions and formulations described herein may omit any component, substitute any component disclosed herein, or include any component disclosed elsewhere herein. The ratios of the mass of any component of any of the compositions or formulations disclosed herein to the mass of any other component in the formulation or to the total mass of the other components in the formulation are hereby disclosed as if they were expressly disclosed. Should the meaning of any terms in any of the patents or publications incorporated by reference conflict with the meaning of the terms used in this disclosure, the meanings of the terms or phrases in this disclosure are controlling. Furthermore, the foregoing discussion discloses and092012-0079-W001

[0214] describes merely exemplary embodiments. All patents and publications cited herein are incorporated by reference herein for the specific teachings thereof.

[0215] Various embodiments and aspects of the inventions described herein are summarized by the following clauses:

[0216] Clause 1. A biosensor device, comprising:

[0217] a field-effect transistor (FET) comprising a gate terminal, a source terminal, and a drain terminal; and

[0218] a sensing electrode electrically connected to the gate terminal of the FET, the sensing electrode configured to capture a target analyte directly or indirectly; wherein the biosensor device is configured to detect the target analyte based on a change in an electrical characteristic of the FET.

[0219] Clause 2. The biosensor device of clause 1, wherein the FET comprises an n-type enhancement mode metal-oxide-semiconductor FET (MOSFET).

[0220] Clause 3. The biosensor device of clause 1 or 2, wherein the sensing electrode comprises a gold electrode.

[0221] Clause 4. The biosensor device of any one of clauses 1-3, wherein the gold electrode comprises a titanium adhesion layer and a gold layer deposited on the titanium adhesion layer.

[0222] Clause s. The biosensor device of any one of clauses 1-4, wherein the target analyte comprises a nanocarrier.

[0223] Clause 6. The biosensor device of any one of clauses 1-5, wherein the nanocarrier comprises an extracellular vesicle, exomere, supermere, lipoprotein, virus, or combinations thereof.

[0224] Clause 7. The biosensor device of any one of clauses 1-6, wherein the sensing electrode is configured to capture the target analyte using a first binding moiety specific for a first marker.

[0225] Clause 8. The biosensor device of any one of clauses 1-7, wherein the biosensor device is configured to detect the target analyte using a second binding moiety specific for a second marker on the same target analyte.

[0226] Clause 9. The biosensor device of any one of clauses 1-8, wherein the target analyte is a nanocarrier that co-localizes the first marker and the second marker.

[0227] Clause 10. The biosensor device of any one of clauses 1-9, wherein the second binding moiety is associated with a charged reporter particle.092012-0079-W001

[0228] Clause 11. The biosensor device of any one of clauses 1-10, wherein the charged reporter particle comprises a magnetic particle or a non-magnetic silica particle.

[0229] Clause 12. The biosensor device of any one of clauses 1-11, wherein the charged reporter particle is configured to modulate the electrical characteristic of the FET when positioned proximate to the sensing electrode to quantify the target analyte.

[0230] Clause 13. The biosensor device of any one of clauses 1-13, wherein the biosensor device is configured to detect the target analyte using a third binding moiety specific for a third marker on the same target analyte.

[0231] Clause 14. The biosensor device of any one of clauses 1-15, wherein the electrical characteristic comprises one or more of drain current, threshold voltage, transconductance, or a transfer characteristic curve.

[0232] Clause 15. The biosensor device of any one of clauses 1-16, wherein the FET is operated in a subthreshold regime.

[0233] Clause 16. The biosensor device of any one of clauses 1-17, further comprising a microfluidic channel positioned adjacent to the sensing electrode.

[0234] Clause 17. The biosensor device of any one of clauses 1-16, further comprising an ion exchange membrane positioned within or adjacent to the microfluidic channel.

[0235] Clause 18. The biosensor device of any one of clauses 1-17, further comprising one or more electrodes configured to apply an electric field across the ion exchange membrane to generate an ion depletion zone proximate to the sensing electrode.

[0236] Clause 19. The biosensor device of any one of clauses 1-18, wherein the sensing electrode is functionalized with probe molecules at a high density to selectively bind the target analyte with high affinity.

[0237] Clause 20. The biosensor device of any one of clauses 1-19, wherein the probe molecules comprise one or more antibodies or nucleic acid probes.

[0238] Clause 21. The biosensor device of any one of clauses 1-20, wherein the target analyte comprises microRNA sequences and the nucleic acid probes are configured to hybridize with the microRNA sequences.

[0239] Clause 22. A biosensor device, comprising:

[0240] a field-effect transistor (FET) comprising a gate terminal, a source terminal, and a drain terminal;

[0241] a sensing electrode electrically connected to the gate terminal of the FET, the sensing electrode configured to capture target biomolecules;

[0242] a microfluidic channel positioned adjacent to the sensing electrode;092012-0079-W001

[0243] an ion exchange membrane (IEM) positioned within the microfluidic channel; and a pair of electrodes configured to apply an electric field across the IEM to generate an ion depletion zone in a region of the microfluidic channel proximate to the sensing electrode.

[0244] Clause 23. The biosensor device of clause 22, wherein the IEM comprises a cation exchange membrane.

[0245] Clause 24. The biosensor device of clause 22 or 23, wherein the cation exchange membrane comprises sulphonate ion-exchange groups.

[0246] Clause 25. The biosensor device of any one of clauses 22-24, wherein the IEM comprises an anion exchange membrane.

[0247] Clause 26. The biosensor device of any one of clauses 22-25, further comprising a pair of buffer reservoirs positioned at opposite ends of the microfluidic channel, wherein the I EM is positioned beneath at least one of the buffer reservoirs.

[0248] Clause 27. The biosensor device of any one of clauses 22-26, wherein the pair of electrodes comprises platinum electrodes positioned within the buffer reservoirs.

[0249] Clause 28. The biosensor device of any one of clauses 22-27, wherein the ion depletion zone is configured to reduce local ionic strength from about 150 mM to below about 0.001 mM. Clause 29. A method for detecting or quantifying target nanocarriers, the method comprising:

[0250] contacting a sample comprising nanocarriers with a first binding reagent specific for a first marker;

[0251] capturing target nanocarriers expressing the first marker;

[0252] contacting the captured target nanocarriers with a second binding reagent specific for a second marker; and

[0253] measuring an electrical characteristic of a field-effect transistor (FET) to detect or quantify target nanocarriers that co-localize the first marker and the second marker on the same nanocarrier.

[0254] Clause 30. The method of clause 29, wherein the second binding reagent is associated with a charged reporter particle.

[0255] Clause 31. The method of clause 29 or 30, wherein the charged reporter particle comprises a magnetic particle or a non-magnetic silica particle.

[0256] Clause 32. The method of any one of clauses 29-30, further comprising washing to remove nonspecifically associated reporter particles prior to measuring the electrical characteristic.092012-0079-W001

[0257] Clause 33. The method of any one of clauses 29-32, wherein the nanocarriers comprise extracellular vesicles.

[0258] Clause 34. The method of any one of clauses 29-33, wherein measuring the electrical characteristic comprises measuring drain current as a function of gate voltage.

[0259] Clause 35. The method of any one of clauses 29-34, wherein the FET is operated in a subthreshold regime.

[0260] Clause 36. The method of any one of clauses 29-35, further comprising releasing, cleaving, or dissociating the nanocarriers after detecting the first marker and the second marker, and re-capturing or re-detecting the nanocarriers using a third binding reagent specific for a third marker.

[0261] Clause 37. The method of any one of clauses 29-36, further comprising lysing the detected or quantified nanocarriers and measuring one or more cargo molecules.

[0262] Clause 38. The method of any one of clauses 29-37, wherein the quantified nanocarriers are used to normalize the one or more cargo molecules.

[0263] Clause 39. The method of any one of clauses 29-38, further comprising generating an ion depletion zone proximate to a sensing electrode by applying an electric field across an ion exchange membrane, wherein the sensing electrode is electrically connected to a gate terminal of the FET.

[0264] Clause 40. A method for detecting a target analyte, the method comprising:

[0265] providing a biosensor device comprising a field-effect transistor (FET) having a sensing electrode electrically connected to a gate terminal of the FET;

[0266] introducing a sample containing the target analyte into the biosensor device; capturing the target analyte on the sensing electrode; and

[0267] measuring an electrical characteristic of the FET to detect the target analyte.

[0268] Clause 41. The method of clause 40, wherein the target analyte comprises a microRNA. Clause 42. The method of clause 40 or 41, wherein the microRNA comprises at least one of miR-21, miR-9, or miR-101-5p.

[0269] Clause 43. The method of any one of clauses 40-42, wherein the target analyte comprises a nanocarrier.

[0270] Clause 44. The method of any one of clauses 40-43, wherein the nanocarrier comprises extracellular vesicles.

[0271] Clause 45. The method of any one of clauses 40-44, wherein the extracellular vesicles are detected using one or more charged reporter particles.092012-0079-W001

[0272] Clause 46. The method of any one of clauses 40-45, wherein the extracellular vesicles comprise surface proteins comprising CD63, CD81, ora combination thereof.

[0273] Clause 47. The method of any one of clauses 40-46, wherein the surface proteins of the extracellular vesicles comprise disease-associated protein biomarkers.

[0274] Clause 48. The method of any one of clauses 40-47, wherein measuring the electrical characteristic of the FET comprises measuring a transfer characteristic curve by sweeping a gate voltage while maintaining a fixed drain-source voltage.

[0275] Clause 49. The method of any one of clauses 40-48, wherein measuring the transfer characteristic curve comprises operating the FET in a subthreshold regime.

[0276] Clause 50. The method of any one of clauses 40-49, wherein the biosensor device further comprises a microfluidic channel positioned adjacent to the sensing electrode, and an ion exchange membrane (IEM) positioned within or adjacent to the microfluidic channel. Clause 51. The method of any one of clauses 40-50, further comprising applying an electric field across the IEM to generate an ion depletion zone proximate to the sensing electrode. Clause 52. The method of any one of clauses 40-51, wherein applying the electric field comprises applying a DC voltage of about 5 V to about 200 across the IEM.

[0277] Clause 53. The method of any one of clauses 40-51, further comprising incubating the sample on the sensing electrode for a period of about 30 minutes to about 60 minutes prior to applying the electric field.

[0278] Clause 54. The method of clause 51, wherein generating the ion depletion zone reduces local ionic strength from about 150 mM to below about 0.001 mM, thereby increasing an effective Debye length to greater than about 100 nm.

[0279] Clause 55. A biosensor system, comprising:

[0280] a biochip comprising a chip substrate, an inlet, an outlet, and a plurality of sensors; a field-effect transistor (FET) electrically connected to at least one of the plurality of sensors; and

[0281] a measurement circuit configured to measure drain current of the FET as a function of gate voltage.

[0282] Clause 56. The biosensor system of clause 55, wherein the biochip further comprises a microfluidic channel extending between the inlet and the outlet, at least one buffer reservoir, and an ion exchange membrane (IEM) positioned beneath the at least one buffer reservoir, the plurality of sensors being positioned within the microfluidic channel.092012-0079-W001

[0283] Clause 57. The biosensor system of clause 55 or 56, further comprising a voltage source configured to apply an electric field across the IEM to generate an ion depletion zone within the microfluidic channel.

[0284] Clause 58. The biosensor system of any one of clauses 55-57, wherein the biochip comprises a pair of buffer reservoirs positioned at opposite ends of the microfluidic channel, and wherein the IEM comprises a cation exchange membrane or an anion exchange membrane positioned beneath each of the buffer reservoirs.

[0285] Clause 59. The biosensor system of any one of clauses 55-58, further comprising platinum electrodes positioned within the pair of buffer reservoirs and configured to receive a DC voltage of about 5 V to about 200 V from a voltage source.

[0286] Clause 60. The biosensor system of any one of clauses 55-59, wherein the plurality of sensors comprises gold electrodes functionalized with probe molecules configured to selectively bind target biomolecules.

[0287] Clause 61. The biosensor system of any one of clauses 55-60, wherein the probe molecules comprise at least one of nucleic acid probes or antibodies.

[0288] Clause 62. The biosensor system of any one of clauses 55-61, wherein the measurement circuit is configured to operate the FET in a subthreshold regime to maximize sensitivity to surface charge perturbations induced by biomolecular binding events.

[0289] Clause 63. A method for enhancing sensitivity of a field-effect transistor (FET) biosensor, the method comprising:

[0290] providing a FET biosensor having a sensing electrode functionalized with probe molecules for capturing target biomolecules;

[0291] positioning an ion exchange membrane (IEM) within a microfluidic channel adjacent to the sensing electrode of the FET biosensor;

[0292] introducing a sample into the microfluidic channel; and

[0293] applying an electric field across the IEM to deplete ions from a region proximate to the sensing electrode, thereby increasing an effective Debye length and enhancing electrostatic coupling between the target biomolecules and the sensing electrode. Clause 64. The method of clause 63, wherein applying the electric field comprises applying a DC voltage of about 5 V to about 200 V across the IEM.

[0294] Clause 65. The method of clause 63 or 64, wherein depleting ions from the region proximate to the sensing electrode reduces local ionic strength from about 150 mM to below about 0.001 mM.092012-0079-W001

[0295] Clause 66. The method of any one of clauses 63-65, wherein the effective Debye length is increased to greater than about 100 nm.

[0296] Clause 67. The method of any one of clauses 63-66, wherein the probe molecules comprise at least one of nucleic acid probes configured to hybridize with target microRNA sequences or antibodies configured to bind target protein markers.

[0297] Clause 68. The method of any one of clauses 63-67, further comprising measuring a transfer characteristic curve of the FET biosensor by sweeping a gate voltage while maintaining a fixed drain-source voltage, wherein the FET biosensor is operated in a subthreshold regime to maximize sensitivity to surface charge perturbations.

[0298] Clause 69. Use of a biosensor device for detecting target biomolecules in a physiological sample, the biosensor device comprising a field-effect transistor (FET) having a sensing electrode, a microfluidic channel, and an ion exchange membrane (IEM), wherein an electric field is applied across the IEM to generate an ion depletion zone proximate to the sensing electrode to reduce ionic strength and extend Debye length during detection. Clause 70. The use of clause 69, wherein the target biomolecules are charged and comprise at least one of microRNA, extracellular vesicles (EVs), supermeres, exomeres, lipoproteins, proteins, or viruses.

[0299] EXAMPLES

[0300] Membrane ion depletion technologies can decrease the local ionic strength near a sensor to DI conditions to amplify the charge signal. The described biosensor technology uses surface functionalized antibodies, oligos and other probes to capture nucleic acids, proteins, and other biomarkers. The charge on these biomarkers or on charged reporters allow quantitation of target molecules. Limits of detection for nucleic acid and proteins are from pM to nM, while those for exosomes and other nanocarriers is in the fM range.

[0301] The ability of the membrane ion depletion module to deplete ions near a sensor and maintain it as DI water conditions suggest that it can also improve the sensitivity and robustness of FET sensors. The membrane ion depletion technologies have been integrated with an EG-FET sensor (MEFET). It has been verified that MEFET can achieve fM detection limit for miRNA with just the low-cost and commercially available EGFET, significantly better than the nM and pM detection limit for the membrane sensor in the above patents. It is expected that the detection limit is even better for exosomes and lipoproteins whose size requires a large Debye layer (low ionic strength) for optimum detection sensitivity.092012-0079-W001

[0302] A bio-FET device, specifically EG-FET, was constructed for femtomolar detection of microRNAs. The platform utilizes commercial n-type MOSFETs coupled to a gold-coated gate electrode, which were functionalized with DNA probes targeting disease-relevant miRNAs. To overcome Debye screening in physiological media, the sensing region was embedded within a microfluidic ion depletion module.

[0303] Overview of the System

[0304] The disclosed sensing platform integrates:

[0305] (1) A field-effect transistor (FET) operating in extended-gate configuration;

[0306] (2) An ion exchange membrane (IEM) positioned within a microfluidic channel;

[0307] (3) An applied electric field to induce ion depletion near the sensing interface; and (4) A functionalized sensing electrode for selective biomolecule capture.

[0308] The ion-depletion region reduces ionic strength locally, thereby increasing the effective Debye length and enhancing electrostatic coupling between target molecules and the FET gate.

[0309] Device Architecture

[0310] FET Configuration

[0311] G30N02T n-type enhancement mode metal-oxide-semiconductor field-effect transistor (MOSFET) was purchased from Goford Semiconductor and operated in extended-gate configuration, which comprises:

[0312] G30N02T MOSFET

[0313] Solderless breadboard FIT0096 (purchased from DFRobot)

[0314] Extended gold gate electrode (custom fabricated)

[0315] Source and drain connected to semiconductor channel

[0316] The sensing electrode is electrically connected to the MOSFET gate via a conductive gold trace.

[0317] Typical Parameters:

[0318] Drain-source bias (VDS): 0.05 V

[0319] Gate bias range: -2 V to +2 V (relative to reference)

[0320] Ion Exchange Membrane (IEM)

[0321] The IEM was positioned under the two reservoirs within a microfluidic channel. The membrane was purchased from Mega A. S. (Czech Republic) and comprised:092012-0079-W001

[0322] Ion-exchange group: sulphon (R-SO3’) for Cation Exchange Membrane (CEM) and Quaternary Ammonium (R–(CH3)3N+) for Anion Exchange Membrane (AEM)

[0323] Ionic form - counterion: Sodium (Na+) for CEM and Cl-for AEM

[0324] Basic binder on base: polyethylene (PE)

[0325] Fitting fabrics: polyester (PES)

[0326] I EM Properties:

[0327] Thickness: ~300 pm

[0328] For CEM: allows cation transport and rejects anions

[0329] For AEM: allows anion transport and rejects cations

[0330] Permselectivity: 0.5 / 0.1M KCI > 90%

[0331] Microfluidic Chip

[0332] A polycarbonate sheet was used to fabricate the microfluidic chip. The microfluidic channel was designed with dimensions of 3.5 cm in length, 2 mm in width, and 300 pm in height, corresponding to a total internal volume of approximately 21 pL. The buffer reservoir was 3D printed using a Stereolithography (SLA) 3D printer. 3D printing resin was purchased from Any Cubic, and polycarbonate sheets were obtained from Tap Plastics.

[0333] Fabrication Methods

[0334] Extended Gate Fabrication

[0335] First, the electrode pattern was formed on a thin plastic film supported on a polycarbonate sheet. Gold electrodes were subsequently fabricated using an Angstrom e-beam evaporation system, beginning with deposition of a 5 nm Ti adhesion layer, followed by a 100 nm Au layer. The thin plastic film was then peeled off to reveal the electrode pattern. The fabricated electrode was subsequently wire-bonded to the MOSFET gate terminal.

[0336] Integration of I EM into the Sensing Chip

[0337] Two 3 mm lEMs were cut and affixed to the two openings on the microfluidic channel of the chip, followed by the bonding of the buffer reservoirs. Platinum (Pt) electrodes were subsequently inserted into the reservoirs to apply the electric field using a Keithley SourceMeter. A photograph of the assembled chip is shown in FIG. 1 B, and a schematic of the chip is shown in FIG. 1C.092012-0079-W001

[0338] Functionalization of Probes on the Sensor Surface

[0339] First, the gold electrode sensor was cleaned by oxygen plasma treatment for 10 minutes. The chip was subsequently immersed in a 5 nM solution of 11-mercaptoundecanoic acid (11-MUA) in ethanol for 48 hours to form a carboxyl-terminated self-assembled monolayer on the gold electrode surface. 1 pM nucleic acid or antibody probes were then covalently conjugated to the surface via EDC / NHS coupling chemistry. The remaining surface was subsequently passivated with PEG-thiol or BSAto reduce non-specific biomolecular adsorption.

[0340] Ion Depletion Operation

[0341] A DC voltage (5-200 V) was applied across the two membrane reservoirs. Due to the ion selectivity of the CEM, cations pass through the membrane, whereas anion are rejected, leading to the formation of an ion depletion zone on one side of the membrane in the microfluidic channel. This depletion markedly reduces the local ionic strength, effectively creating a deionized-water-like environment within the channel. Such a condition not only suppresses Debye screening but also provides a consistent ionic environment during signal measurement, thereby improving sensor reliability and sensitivity. The local ionic strength was estimated to decrease from 1 x PBS (~150 mM) to below 0.001 mM, while the Debye length correspondingly increased from ~0.7 nm to >100 nm, resulting in enhanced electrostatic gating.

[0342] Experimental Methods

[0343] Baseline Measurement

[0344] Buffer introduced (PBS 0.1 X-1 X)

[0345] FET operated at fixed VDs

[0346] Transfer curve ( / Dvs. VG) measured

[0347] Threshold voltage extracted

[0348] Detection Protocol

[0349] Sample introduced (e.g., miRNA, EV suspension)

[0350] Capture incubation (30-60 min)

[0351] Apply depletion voltage across CEM

[0352] Record FET transfer curve

[0353] Measured Parameters:

[0354] Threshold voltage shift ( T)092012-0079-W001

[0355] Change in drain current (ΔID)

[0356] The FET sensor was first functionalized with target specific probes. The FET sensor was then equilibrated with PBS buffer (0.1-1x), and baseline electrical characteristics were recorded. The device was operated at a fixed drain-source voltage (VDS), and the transfer curve was obtained by measuring drain current ( / D) as a function of gate voltage ( VG). The threshold voltage was then extracted from the baseline transfer characteristics.

[0357] For target detection, the sample solution, such as miRNAs, antigens, supermeres, exomeres, HDL, or extracellular vesicle (EV) suspension, was introduced onto the sensor and incubated for 30 min to allow target capture. For weakly or uncharged targets such as antigen, EVs, exomeres, or HDL, the charged silica or magnetic beads attached to a detection antibody were used as a reporter and incubated for another 30 minutes. Following incubation, a depletion voltage was applied across the cation-exchange membrane (CEM). The FET transfer curve was then recorded again under the same operating conditions. Sensor response was quantified by analyzing the shift in drain current (ΔID).

[0358] Target Biomolecules

[0359] Applicable targets included:

[0360] miRNA (e.g., miR-21, miR-9, miR-101-5p; 10 fM to 1 nM range)

[0361] Extracellular Vesicles (105to 109particles / mL): CD63+ EVs; CD81+ EVs Supermeres: HSPA13+ supermeres

[0362]

[0363] Multi-Marker Nanocarrier Quantification - Detection of Co-Localized EV Markers using Cleavable Reporters092012-0079-W001

[0364] First, EVs were isolated from the sample using magnetic beads conjugated to an antibody against EV-specific marker 1. After 30 minutes of incubation, the bead-bound EVs were collected and washed using a magnetic separator. The magnetic bead-bound EVs were then introduced to a FET sensor functionalized with an antibody against marker 2 and incubated for 30 minutes prior to signal measurement. The sensor was subsequently treated with a cleavage buffer to remove the magnetic beads from the EV surface, followed by washing and a second signal measurement. The EVs were then incubated with a new set of magnetic beads conjugated to an antibody against marker 3.

[0365] Experimental Results

[0366] Referring to FIG. 3, a calibration curve illustrates the normalized change in drain current as a function of analyte concentration for miR-101-5p detection under three different ionic conditions that were tested. The vertical axis represents the normalized change in drain current in arbitrary units, ranging from 0.0 to 1.0. The horizontal axis represents the concentration in molar units, displayed on a logarithmic scale spanning from 10-15to 10-5M. Three distinct curves are presented, each corresponding to a different experimental condition: a depletion condition, a 0.1x PBS condition, and a 1X PBS condition.

[0367] The depletion condition curve exhibits the leftmost position among the three curves, indicating the highest sensitivity with detectable signal changes occurring at concentrations as low as approximately 10-15M. The 0.1x PBS condition curve is shifted to the right relative to the depletion curve, showing intermediate sensitivity. The 1x PBS condition curve is positioned furthest to the right, demonstrating the lowest sensitivity among the three conditions. Each data point includes error bars indicating measurement variability. Each calibration curve exhibits a sigmoidal response characteristic. The sigmoidal shape reflects the characteristic binding response of the sensor across the concentration range tested. At low concentrations, the signal remains near baseline levels where target analyte binding was insufficient to produce a measurable change in drain current. As concentration increases through the mid-range, the signal increased steeply as more target analyte molecules bind to the probe molecules on the sensing electrode. At higher concentrations, the signal approached saturation as the available binding sites on the sensing electrode became occupied.

[0368] The horizontal separation between the three calibration curves in FIG. 3 demonstrates the effect of ionic strength on detection sensitivity. Under the 1x PBS condition, which corresponds to physiological ionic strength of approximately 150 mM, the Debye screening effect limits the electrostatic coupling between captured target analyte molecules and the sensing electrode. The092012-0079-W001

[0369] 0.1X PBS condition provides reduced ionic strength compared to physiological conditions, resulting in an extended Debye length and improved sensitivity as reflected by the leftward shift of the calibration curve. The depletion condition provides the lowest ionic strength environment proximate to the sensing electrode, resulting in the greatest extension of the Debye length and the highest detection sensitivity.

[0370] Referring to FIG. 4, a bar graph compares the limit of detection in molar concentration for miR-101-5p under the three buffer conditions. The depletion condition exhibited a limit of detection of approximately 10-15M for miR-101-5p. The 0.1X PBS condition exhibited an intermediate limit of detection of approximately 10’12M. The 1X PBS condition exhibited a limit of detection of approximately 10"10M. The comparison demonstrated that using the depletion condition improves the limit of detection by approximately four to five orders of magnitude compared to the 1X PBS physiological condition. The improvement in detection limit achieved through ion depletion may be attributed to the reduction in Debye screening effects. Under the 1X PBS condition, the Debye length of approximately 0.7 nm limits the distance over which electrostatic interactions between charged target analyte molecules and the sensing electrode can occur. When ion depletion reduces the local ionic strength to below 0.001 mM, the Debye length increases to greater than 100 nm, enabling electrostatic coupling over distances that encompass the captured target analyte molecules. This extended Debye length allows the charge associated with bound microRNA molecules to modulate the gate potential of the field-effect transistor, resulting in a measurable change in drain current at concentrations that would be undetectable under physiological ionic strength conditions. The four to five orders of magnitude improvement in both sensitivity and dynamic range achieved through ion depletion enables detection of microRNA such as miR-101-5p at femtomolar concentrations. This detection limit approaches the sensitivity achievable with amplification-based techniques such as RT-PCR while maintaining the advantages of label-free, real-time detection associated with field-effect transistor biosensors. The consistent low ionic strength environment provided by the ion depletion approach may also improve reproducibility by eliminating variability associated with ionic strength fluctuations in physiological samples.

[0371] Referring to FIG. 5, a graph illustrates transfer characteristic curves of drain current as a function of gate voltage for miR-101-5p detection under 1X PBS condition. The vertical axis represents drain current in amperes on a logarithmic scale ranging from 10-10to 100 amperes. The horizontal axis represents gate voltage in volts ranging from 0.0 to 1.0 volts. Multiple curves are displayed corresponding to different concentrations of miR-101-5p, including a baseline measurement and concentrations spanning from 1 fM to 10 M. The curves in FIG. 5 exhibit092012-0079-W001

[0372] characteristic transistor behavior with drain current increasing as gate voltage increases, transitioning from a subthreshold regime at lower gate voltages to a linear regime at higher gate voltages. Under the 1X PBS condition, which corresponds to physiological ionic strength of approximately 150 mM, the curves for different miR-101-5p concentrations are closely spaced and largely overlapping throughout the measured gate voltage range. The minimal separation between concentration-dependent responses under the 1x PBS condition reflects the Debye screening effect, where the short Debye length of approximately 0.7 nm limits the electrostatic coupling between captured microRNA molecules and the sensing electrode.

[0373] FIG. 6 shows a graph of transfer characteristic curves showing drain current as a function of gate voltage for miR-101-5p detection under 0.1 x PBS condition. Compared to the 1x PBS condition shown in FIG. 5, the transfer curves under the 0.1x PBS condition exhibited improved separation between different miR-101-5p concentrations. The curves show a progressive shift with increasing miR-101-5p concentration, with higher concentrations producing distinguishable shifts in the transfer characteristics compared to the baseline measurement. The improved separation between concentration-dependent responses under the 0.1x PBS condition may be attributed to the reduced ionic strength, which extends the Debye length and enhances electrostatic coupling between captured microRNA molecules and the sensing electrode. The 0.1x PBS condition provides an intermediate ionic strength environment that partially mitigates Debye screening effects while maintaining compatibility with sample handling requirements.

[0374] FIG. 7 shows a graph of transfer characteristic curves showing drain current as a function of gate voltage for miR-101-5p detection using the depletion module. As shown in FIG. 7, the curves demonstrate characteristic transistor transfer behavior with an exponential increase in drain current in the subthreshold regime at lower gate voltages, transitioning to a more linear increase at intermediate gate voltages, and approaching saturation at higher gate voltages. The transfer curves under the depletion condition show progressive shifts with increasing analyte concentration, with higher concentrations corresponding to curves positioned toward the right side of the plot. The progressive shift pattern across the concentration range from femtomolar to nanomolar demonstrates the enhanced dynamic range achieved through ion depletion. The separation between transfer curves at different miR-101-5p concentrations shown in FIG. 7 is substantially greater under the depletion condition compared to both the 1 x PBS condition shown in FIG. 5 and the 0.1x PBS condition shown in FIG. 6. The enhanced separation enables discrimination between different target analyte concentrations across a wide dynamic range spanning from femtomolar to nanomolar concentrations. The ion depletion approach reduces the local ionic strength proximate to the sensing electrode to below 0.001 mM, which increases the092012-0079-W001

[0375] effective Debye length to greater than 100 nm. This extended Debye length enables the charge associated with captured microRNA molecules to modulate the gate potential of the field-effect transistor over distances that encompass the hybridized target molecules, resulting in measurable shifts in the transfer characteristics even at femtomolar concentrations. The data illustrated in FIG. 7 demonstrates that the ion depletion approach enables detection of microRNA such as miR-101-5p across a concentration range that would be inaccessible using conventional field-effect transistor biosensors operated under physiological ionic strength conditions.

[0376] Referring to FIG. 8, a graph illustrates transfer characteristic curves showing drain current as a function of gate voltage for miR-9 detection using the depletion module. The transfer characteristic curves depicted in FIG. 8 demonstrate characteristic S-shaped transfer behavior with drain current increasing exponentially in the subthreshold regime and transitioning to a more gradual increase in the linear and saturation regimes. The curves show progressive shifts in response to increasing miR-9 concentrations, with higher concentrations producing measurable changes in the transfer characteristics relative to the baseline measurement. The baseline curve represents the initial transfer characteristics of the sensor prior to exposure to miR-9 target sequences. In FIG. 8, the separation between transfer curves at different miR-9 concentrations demonstrates the ability of the biosensor device to discriminate between different target analyte concentrations when operated under ion depletion conditions. The progressive rightward shift of the transfer curves with increasing miR-9 concentration reflects the accumulation of negatively charged microRNA molecules on the sensing electrode through hybridization with complementary nucleic acid probes. The negative charge associated with the captured miR-9 molecules modulates the effective gate potential of the field-effect transistor, resulting in shifts in the transfer characteristics that correlate with target analyte concentration. The extended Debye length achieved through ion depletion enables electrostatic coupling between the captured miR-9 molecules and the gate interface across the concentration range from 10 fM to 1 pM.

[0377] Referring to FIG. 9, a calibration plot illustrates the normalized change in drain current as a function of miR-9 concentration under ion depletion conditions. The calibration curve exhibits a sigmoidal response characteristic. The signal remained near baseline at low concentrations where target analyte binding was insufficient to produce a measurable change in drain current. The signal increased steeply through the mid-range concentrations as more miR-9 molecules hybridize with complementary probes on the sensing electrode. The signal approached saturation at higher concentrations as the available binding sites on the sensing electrode become occupied. The Logistic5 fit of FIG. 9 provides a mathematical model for the concentration-dependent response that may be used for quantification of unknown samples. The limit of detection for miR-092012-0079-W001

[0378] 9 was indicated as 100 femtomolar, which demonstrates the high sensitivity achieved using the ion depletion approach for miR-9 detection. The femtomolar detection limit for miR-9 is consistent with the femtomolar detection limits observed for miR-101-5p under ion depletion conditions with reference to FIG. 4. The calibration data presented in FIG. 9 demonstrates that the ion depletion approach enables quantitative detection of miR-9 across a concentration range spanning several orders of magnitude, from femtomolar to micromolar concentrations. The wide dynamic range and low detection limit achieved for miR-9 detection may enable applications in disease biomarker detection where microRNA concentrations in physiological samples may be present at low abundance levels.

[0379] Biosensor Configuration

[0380] Referring to FIG. 10A, a diagram illustrates an exemplary biosensor array layout showing a grid arrangement of electrodes with an interconnecting trace pattern. The example sensor array comprises six columns labeled 1-6, and six rows labeled A-F. Each intersection of a row and column contains a circular electrode element connected by a serpentine trace that winds through the array. A filled circle is positioned at the intersection of row A and column 1, indicating an active or selected electrode position designated as electrode A1. The serpentine trace connects all electrodes in a continuous path in the electrode grid. The serpentine trace pattern provided electrical connectivity between the electrodes and enabled sequential addressing of individual electrodes within the array.

[0381] In FIG. 10A, a corresponding transfer characteristic curve is shown illustrating drain current measurements for electrode A1. The vertical axis represents drain current in amperes on a logarithmic scale ranging from 10-11A to 10-1A. The horizontal axis represents gate voltage in volts ranging from 0.0 V to 1.0 V. The curve shows the drain current increasing from approximately 10-9A at 0.0 V gate voltage to approximately 10-1A at 1.0 V gate voltage. The curve exhibits an exponential increase in drain current in the subthreshold regime at lower gate voltages, transitioning to a more gradual increase as the gate voltage approaches 1.0 V, where the drain current begins to plateau in the saturation regime. The overlapping nature of the three A1 data series indicated reproducibility of the transfer characteristic measurement for the active sensing electrode A1.

[0382] Referring to FIG. 10B, a diagram illustrates signal measurement under different electrode configurations from FIG. 10A. A partial graph is shown displaying drain current in amperes on a logarithmic scale ranging from 10’11to 10-1, with data traces visible near the 10’9level. The electrode configuration depicted in FIG. 10B enabled assessment of whether neighboring092012-0079-W001

[0383] electrodes influence the signal measured at the active sensing electrode. The neighboring electrodes at positions A2, A3, and B1 were positioned immediately adjacent to the active sensing electrode at position A1, representing the closest electrodes that could potentially contribute to crosstalk effects.

[0384] FIG. 10C shows a diagram of the sensor array configuration with electrode positions and a corresponding graph of drain current measurements. The data points correspond to the active sensing electrode and demonstrate signal measurements under different electrode connections. The measurements illustrate that neighboring electrodes did not measurably influence the signal of the active sensing electrode. No detectable crosstalk was observed in the electrode array design. The biosensor may comprise multiple sensing electrodes configured such that neighboring electrodes do not measurably influence the signal of the active sensing electrode with no detectable crosstalk. The absence of crosstalk between neighboring electrodes enables independent measurement of signals from individual sensing electrodes within the array. This configuration may allow multiplexed detection of multiple target analytes using different sensing electrodes within the same biochip, where each sensing electrode may be functionalized with different probe molecules for selective capture of different target biomolecules. The electrode array configuration with the serpentine trace pattern provides a scalable architecture for biosensor devices that may accommodate multiple sensing electrodes while maintaining signal integrity at each individual electrode position.

[0385] Selectivity and Mismatch Discrimination

[0386] Referring to FIG. 11, a bar graph illustrates sensor selectivity when sensors were functionalized with Probe-9 and Probe-21 and treated with complementary miR-9 and miR-21 target sequences. The vertical axis represents the change in drain current (A / D) measured in arbitrary units (a.u.), ranging from 0.0 to 0.6. The horizontal axis displays six experimental conditions defined by the presence or absence of Probe-9, Probe-21, miR-9, and miR-21, as indicated by plus and minus symbols beneath each bar. As shown in FIG. 11, the first condition shows Probe-9 alone with no target, yielding a minimal signal near zero. The second condition shows Probe-9 with miR-21, which is a non-complementary target, also yielding a minimal signal near zero. The third condition shows Probe-9 with its complementary target miR-9, producing a high signal of approximately 0.45 a.u. The fourth condition shows Probe-21 alone with no target, yielding a minimal signal near zero. The fifth condition shows Probe-21 with miR-9, which is a non-complementary target, yielding a low signal of approximately 0.08 a.u. The sixth condition shows Probe-21 with its complementary target miR-21, producing a high signal of approximately092012-0079-W001

[0387] 0.45 a.u. Individual data points are displayed as open circles overlaid on each bar, and error bars indicate measurement variability. The results demonstrate that a matching probe and target combination yields a high shift in drain current, while non-complementary pairs yield minimal signals. The selectivity demonstrated in FIG. 11 indicates that the biosensor device may discriminate between different microRNA sequences based on sequence complementarity between the probe molecules and the target analyte / biomolecules. The minimal signal observed when Probe-9 is exposed to miR-21, and the low signal observed when Probe-21 is exposed to miR-9, indicate that non-specific binding between non-complementary probe-target pairs does not produce substantial changes in drain current. The high signals observed for complementary probe-target pairs (e.g., Probe-9 with miR-9 and Probe-21 with miR-21) demonstrate that hybridization between complementary sequences produces measurable changes in drain current that may be used for target analyte detection and quantification.

[0388] Referring to FIG. 12A, a bar graph illustrates the change in drain current (A / D) measured in arbitrary units (a.u.) for different mismatch conditions in miR-9 sequence detection. The x-axis displays four categories: 3-mismatch, 2-mismatch, 1 -mismatch, and perfect target. The y-axis represents / D values ranging from 0.0 to 0.6 a.u. The 3-mismatch condition shows the lowest signal response at approximately 0.05 a.u., while the 2-mismatch condition exhibits a higher response at approximately 0.19 a.u. The 1 -mismatch condition demonstrates a further increased response at approximately 0.41 a.u., and the perfect target condition shows the highest response at approximately 0.44 a.u. Individual data points are displayed as open circles overlaid on each bar, indicating replicate measurements. Error bars representing measurement variability are shown at the top of each bar. The progressive decrease in signal from perfect match to 3-mismatch conditions demonstrates that the biosensor may be configured to distinguish between perfectly matched and mismatched nucleic acid sequences. For example, the biosensor may discriminate sequences having 1, 2, or 3 nucleotide mismatches from 100% complementary sequences. The signal difference between the perfect target condition and the 1 -mismatch condition was relatively small, with both conditions producing signals above 0.4 a.u. The signal difference between the 1 -mismatch condition and the 2-mismatch condition was more pronounced, with the 2-mismatch condition producing a signal of approximately 0.19 a.u. compared to approximately 0.41 a.u. for the 1-mismatch condition. The 3-mismatch condition produced the lowest signal at approximately 0.05 a.u., which approaches the baseline signal level observed for non-complementary probe-target pairs.

[0389] FIG. 12B shows a graph that illustrates transfer characteristic curves for mismatch studies with the miR-9 sequence, showing signals observed for one mismatch conditions. Five curves092012-0079-W001

[0390] are displayed representing different experimental conditions: a baseline measurement, a 1 pM perfect complementary target sequence, and three separate one mismatch target sequences. The curves demonstrate similar transfer characteristics across all conditions, with drain current increasing exponentially in the subthreshold regime at lower gate voltages and transitioning toward saturation at higher gate voltages approaching 1.0 V. The curves largely overlap throughout the measured gate voltage range, indicating that single nucleotide mismatches produce transfer characteristics that are similar to the perfect complementary sequence under the measurement conditions employed.

[0391] Referring to FIG. 12C, a graph illustrates transfer characteristic curves showing drain current as a function of gate voltage for mismatch studies with the miR-9 sequence. The graph displays multiple curves corresponding to different experimental conditions including a baseline measurement, a 1 pM perfect complementary sequence, and three separate 2 mismatch sequences. The curves demonstrate that the 2 mismatch sequences produced transfer characteristics that closely overlap with each other. The drain current increased exponentially with increasing gate voltage in the subthreshold regime and approached saturation at higher gate voltages near 1.0 volt. The separation between the 2 mismatch curves and the perfect complementary curve indicates that the biosensor may distinguish between perfectly matched sequences and sequences having two nucleotide mismatches based on differences in the transfer characteristics.

[0392] Referring to FIG. 12D, a graph depicts transfer characteristic curves for mismatch studies with the miR-9 sequence for 3 mismatches. The graph displays multiple curves including a baseline curve, a 1 pM perfect complementary curve, and three curves representing 3 mismatch conditions. The baseline and 1 pM perfect complementary curves are positioned slightly lower on the graph, while the three 3 mismatch curves overlap closely with each other at slightly higher current values. All curves demonstrate an exponential increase in drain current as gate voltage increases from 0.0 V to approximately 0.6 V, followed by a plateau region where the drain current approaches 10-1A at higher gate voltages. The slight separation between the perfect complementary curve and the 3 mismatch curves indicated the ability of the biosensor to discriminate between perfectly matched and mismatched sequences. The 3 mismatch sequences show minimal shift from baseline compared to the perfect complementary target, which is consistent with the low signal observed for the 3-mismatch condition in FIG. 12A. The mismatch discrimination capability demonstrated in FIG. 12A-D indicates that the biosensor may be configured to distinguish between perfectly matched and mismatched nucleic acid sequences, including, for example, sequences having 1, 2, or 3 nucleotide mismatches. The progressive092012-0079-W001

[0393] decrease in signal with increasing number of mismatches reflects the reduced hybridization stability between the probe molecules and mismatched target sequences. Sequences with more mismatches exhibit weaker binding to the complementary probe molecules, resulting in fewer target molecules captured on the sensing electrode and correspondingly lower changes in drain current. The mismatch discrimination capability may enable applications in single nucleotide polymorphism detection, mutation analysis, and other applications where discrimination between closely related nucleic acid sequences is desired.

[0394] Detection of Extracellular Vesicles (EVs) and Supermeres

[0395] Referring to FIG. 13A, a graph illustrates transfer characteristic curves for the detection of extracellular vesicles and supermeres. Three curves are presented in the graph: a baseline curve representing the initial transfer characteristics of the sensor prior to sample exposure, a curve corresponding to 1 pM supermere showing the transfer characteristics following exposure to supermere samples at a concentration of 1 pM, and a curve corresponding to 1 pM DiFi EV showing the transfer characteristics following exposure to DiFi cell-derived extracellular vesicles at a concentration of 1 pM. The baseline and 1 pM supermere curves exhibited similar behavior and are positioned close together throughout the voltage range. The 1 pM DiFi EV curve showed a shift toward higher gate voltages, particularly in the subthreshold and linear regimes between approximately 0.1 V and 0.6 V. All three curves converge at higher gate voltages approaching 0.9 V where the drain current approaches saturation near 10’1amperes. The shift observed for the DiFi EV curve relative to the baseline indicates detection of extracellular vesicles captured on the sensing electrode functionalized with anti-CD63 probes. FIG. 13B shows a graph when the sensing electrode was functionalized with anti-HSPA13 probes. The data demonstrates the capability of the biosensor device to distinguish between different types of nanocarriers based on the probe molecules used for functionalization of the sensing electrode.

[0396] Referring to FIG. 13C, a bar graph depicts the change in drain current (A / D) measured in arbitrary units (a.u.) for different experimental conditions involving the detection of CD63-positive extracellular vesicles and HSPA13-positive supermeres. The y-axis represents A / D values ranging from 0.0 to 1.0 a.u., while the x-axis indicates four distinct experimental conditions defined by the presence or absence of Probe-CD63, Probe-HSPA13, EVs, and supermeres. The results demonstrate selective detection of extracellular vesicles and supermeres based on the probe molecules used for functionalization of the sensing electrode. For example, when the sensing electrode was functionalized with anti-CD63 probes, exposure to extracellular vesicles produced a high signal of approximately 0.8 a.u., while exposure to supermeres produced a lower signal of092012-0079-W001

[0397] approximately 0.2 a.u. The high signal observed for the Probe-CD63 with EV condition reflects the presence of CD63 protein markers on the surface of extracellular vesicles, which enables capture of the extracellular vesicles on the sensing electrode through antibody-antigen binding. The lower signal observed for the Probe-CD63 with supermere condition indicates that supermeres have reduced expression of CD63 markers compared to extracellular vesicles. When the sensing electrode was functionalized with anti-HSPA13 probes, exposure to supermeres produces a high signal of approximately 1.0 a.u., while exposure to extracellular vesicles produces a lower signal of approximately 0.4 a.u. The high signal observed for the Probe-HSPA13 with supermere condition reflects the presence of HSPA13 protein markers on the surface of supermeres, which enables capture of the supermeres on the sensing electrode through antibody-antigen binding. The lower signal observed for the Probe-HSPA13 with EV condition indicates that extracellular vesicles have reduced expression of HSPA13 markers compared to supermeres.

[0398] The selective detection demonstrated in FIG. 13C indicates that the biosensor device may be configured to distinguish between different types of extracellular nanoparticles based on their specific surface marker profiles. By functionalizing the sensing electrode with probe molecules that target markers specific to particular nanoparticle populations, the biosensor may enable selective detection and quantification of extracellular vesicles, supermeres, or other nanocarriers in biological samples. The ability to distinguish between CD63-positive extracellular vesicles and HSPA13-positive supermeres may enable applications in biomarker discovery, disease diagnosis, and therapeutic monitoring where different nanoparticle populations carry distinct molecular cargo and biological functions.

[0399] Multi-Marker Detection of Co-Localized EV Markers

[0400] Referring to FIG. 14A, a sequence diagram illustrates an exemplary method for detecting co-localized extracellular vesicle (EV) markers using cleavable reporters. The method enables sequential detection of multiple protein markers on extracellular vesicles through a multi-step process involving magnetic bead capture, sensor binding, cleavage buffer treatment, and sequential marker detection. The exemplary process begins with a magnetic bead conjugated to an antibody against a first marker. An extracellular vesicle, depicted in FIG. 14A as a circular structure with a membrane ring, is present in the sample. The magnetic bead-antibody complex captures the extracellular vesicle through binding of the first marker antibody to corresponding markers on the extracellular vesicle surface. The magnetic bead-bound extracellular vesicles may be collected and washed using a magnetic separator following incubation.092012-0079-W001

[0401] With continued reference to FIG. 14A, in the next stage of the method, the captured extracellular vesicle is brought into contact with a sensor surface. The sensor surface, shown as a textured substrate, is functionalized with antibodies against a second marker, depicted as Y-shaped structures extending from the sensor surface. The extracellular vesicle becomes bound to both the magnetic bead via the first marker and to the sensor surface via the second marker, creating a sandwich configuration. This sandwich configuration enables detection of extracellular vesicles that co-express both the first marker and the second marker on their surface. Following signal measurement, a cleavage buffer is applied to the system. The cleavage buffer treatment removes the magnetic beads from the extracellular vesicle surface while the extracellular vesicle remains bound to the sensor surface through the second marker antibodies. The released first marker antibody and magnetic bead are shown separated from the extracellular vesicle following cleavage buffer treatment. The method may include treating the sensor with the cleavage buffer to remove magnetic beads from the extracellular vesicle surface, followed by washing and a second signal measurement. In the final stage depicted in FIG. 14A, a new set of magnetic beads conjugated to antibodies against a third marker was introduced. These beads bind to the third marker on the extracellular vesicle surface. The resulting configuration shows the extracellular vesicle simultaneously bound to the sensor surface via the second marker antibodies and to the new magnetic beads via the third marker antibodies. The method may include incubating extracellular vesicles with a new set of magnetic beads conjugated to an antibody against a third marker after the second signal measurement. This sequential approach enables detection of multiple co-localized markers on the same extracellular vesicle population.

[0402] For weakly charged or uncharged targets such as antigens, extracellular vesicles, exomeres, or HDL, charged silica beads or magnetic beads attached to a detection antibody may be used as a reporter. In some embodiments, the reporter beads may be incubated with the target for about 30 minutes following initial target capture. The charged reporter beads introduce charge proximate to the sensing electrode, thereby enabling detection through modulation of the field-effect transistor gate potential even when the target analyte itself carries insufficient charge for direct detection.

[0403] Referring to FIG. 14B, a graph depicts transfer characteristic curves for the detection of co-localized extracellular vesicle protein markers. Multiple curves are displayed representing different experimental conditions. The curves demonstrate a shift in the transfer characteristics following the introduction of anti-CD63 magnetic beads compared to the baseline measurements. The shift reflects the presence of charged magnetic beads bound to CD63 markers on extracellular vesicles captured on the sensing electrode. The sequential wash curves show a092012-0079-W001

[0404] progressive shift back toward the baseline, indicating removal of the magnetic beads from the extracellular vesicle surface during the washing process. All curves exhibit characteristic transistor behavior with an exponential increase in drain current in the subthreshold regime at lower gate voltages, transitioning to a saturation regime at higher gate voltages where the drain current plateaus near 10-2amperes.

[0405] Referring to FIG. 14C, a graph depicts transfer characteristic curves for detection of colocalized extracellular vesicle protein markers using both anti-CD63 and anti-CD81 magnetic beads. Multiple transfer curves are displayed representing different experimental conditions. The anti-CD63 and anti-CD81 magnetic bead curves show shifts relative to their respective baseline measurements, indicating successful detection of CD63-positive and CD81 -positive extracellular vesicles. All curves converge toward a saturation drain current of approximately 10’2amperes at gate voltages above 0.6 V. The data presented in FIG. 14C demonstrates the successful detection of two co-localized extracellular vesicle protein markers (e.g., CD63 and CD81) using the sequential magnetic bead approach.

[0406] FIG. 14D shows a graph depicting the change in drain current (A / D) in arbitrary units as a function of step wash number. The graph displays four data points with error bars, showing a decreasing trend in A / D as the step wash number increases. The decreasing trend in A / D with increasing wash number reflected the progressive removal of magnetic beads from the extracellular vesicle surface during the sequential washing steps.

[0407] FIG. 14E shows a box plot comparing the change in drain current (A / D) measured in arbitrary units (a.u.) for two experimental conditions involving anti-CD63 or anti-CD81 magnetic beads. The comparison between the two box plots demonstrates differences in signal magnitude between the two magnetic bead conditions. The higher median A / Dvalue observed for the first condition with the anti-CD63 magnetic beads compared to the second condition with the anti-CD81 magnetic beads may reflect differences in marker expression levels, binding efficiency, or other factors affecting the number of magnetic beads captured on the extracellular vesicle surface. The box plot comparison provides a statistical representation of the signal distribution for each condition, enabling assessment of measurement reproducibility and comparison of signal magnitudes between different experimental conditions.

Claims

1. 092012-0079-W001CLAIMSWhat is claimed:

1. A biosensor device, comprising:a field-effect transistor (FET) comprising a gate terminal, a source terminal, and a drain terminal; anda sensing electrode electrically connected to the gate terminal of the FET, the sensing electrode configured to capture a target analyte directly or indirectly; wherein the biosensor device is configured to detect the target analyte based on a change in an electrical characteristic of the FET.

2. The biosensor device of claim 1, wherein the FET comprises an n-type enhancement mode metal-oxide-semiconductor FET (MOSFET).

3. The biosensor device of claim 1, wherein the sensing electrode comprises a gold electrode.

4. The biosensor device of claim 3, wherein the gold electrode comprises a titanium adhesion layer and a gold layer deposited on the titanium adhesion layer.

5. The biosensor device of claim 1, wherein the target analyte comprises a nanocarrier.

6. The biosensor device of claim 5, wherein the nanocarrier comprises an extracellular vesicle, exomere, supermere, lipoprotein, virus, or combinations thereof.

7. The biosensor device of claim 1, wherein the sensing electrode is configured to capture the target analyte using a first binding moiety specific for a first marker.

8. The biosensor device of claim 7, wherein the biosensor device is configured to detect the target analyte using a second binding moiety specific for a second marker on the same target analyte.

9. The biosensor device of claim 8, wherein the target analyte is a nanocarrier that colocalizes the first marker and the second marker.092012-0079-W00110. The biosensor device of claim 8, wherein the second binding moiety is associated with a charged reporter particle.

11. The biosensor device of claim 10, wherein the charged reporter particle comprises a magnetic particle or a non-magnetic silica particle.

12. The biosensor device of claim 10, wherein the charged reporter particle is configured to modulate the electrical characteristic of the FET when positioned proximate to the sensing electrode to quantify the target analyte.

13. The biosensor device of claim 8, wherein the biosensor device is configured to detect the target analyte using a third binding moiety specific for a third marker on the same target analyte.

14. The biosensor device of claim 1, wherein the electrical characteristic comprises one or more of drain current, threshold voltage, transconductance, or a transfer characteristic curve.

15. The biosensor device of claim 1, wherein the FET is operated in a subthreshold regime.

16. The biosensor device of claim 1, further comprising a microfluidic channel positioned adjacent to the sensing electrode.

17. The biosensor device of claim 16, further comprising an ion exchange membrane positioned within or adjacent to the microfluidic channel.

18. The biosensor device of claim 17, further comprising one or more electrodes configured to apply an electric field across the ion exchange membrane to generate an ion depletion zone proximate to the sensing electrode.

19. The biosensor device of claim 1, wherein the sensing electrode is functionalized with probe molecules at a high density to selectively bind the target analyte with high affinity.092012-0079-W00120. The biosensor device of claim 19, wherein the probe molecules comprise one or more antibodies or nucleic acid probes.

21. The biosensor device of claim 20, wherein the target analyte comprises microRNA sequences and the nucleic acid probes are configured to hybridize with the microRNA sequences.

22. A biosensor device, comprising:a field-effect transistor (FET) comprising a gate terminal, a source terminal, and a drain terminal;a sensing electrode electrically connected to the gate terminal of the FET, the sensing electrode configured to capture target biomolecules;a microfluidic channel positioned adjacent to the sensing electrode;an ion exchange membrane (IEM) positioned within the microfluidic channel; and a pair of electrodes configured to apply an electric field across the IEM to generate an ion depletion zone in a region of the microfluidic channel proximate to the sensing electrode.

23. The biosensor device of claim 22, wherein the IEM comprises a cation exchange membrane.

24. The biosensor device of claim 23, wherein the cation exchange membrane comprises sulphonate ion-exchange groups.

25. The biosensor device of claim 22, wherein the IEM comprises an anion exchange membrane.

26. The biosensor device of claim 22, further comprising a pair of buffer reservoirs positioned at opposite ends of the microfluidic channel, wherein the IEM is positioned beneath at least one of the buffer reservoirs.

27. The biosensor device of claim 26, wherein the pair of electrodes comprises platinum electrodes positioned within the buffer reservoirs.092012-0079-W00128. The biosensor device of claim 22, wherein the ion depletion zone is configured to reduce local ionic strength from about 150 mM to below about 0.001 mM.

29. A method for detecting or quantifying target nanocarriers, the method comprising:contacting a sample comprising nanocarriers with a first binding reagent specific for a first marker;capturing target nanocarriers expressing the first marker;contacting the captured target nanocarriers with a second binding reagent specific for a second marker; andmeasuring an electrical characteristic of a field-effect transistor (FET) to detect or quantify target nanocarriers that co-localize the first marker and the second marker on the same nanocarrier.

30. The method of claim 29, wherein the second binding reagent is associated with a charged reporter particle.

31. The method of claim 30, wherein the charged reporter particle comprises a magnetic particle or a non-magnetic silica particle.

32. The method of claim 30, further comprising washing to remove nonspecifically associated reporter particles prior to measuring the electrical characteristic.

33. The method of claim 29, wherein the nanocarriers comprise extracellular vesicles.

34. The method of claim 29, wherein measuring the electrical characteristic comprises measuring drain current as a function of gate voltage.

35. The method of claim 29, wherein the FET is operated in a subthreshold regime.

36. The method of claim 29, further comprising releasing, cleaving, or dissociating the nanocarriers after detecting the first marker and the second marker, and re-capturing or re-detecting the nanocarriers using a third binding reagent specific for a third marker.092012-0079-W00137. The method of claim 29, further comprising lysing the detected or quantified nanocarriers and measuring one or more cargo molecules.

38. The method of claim 37, wherein the quantified nanocarriers are used to normalize the one or more cargo molecules.

39. The method of claim 29, further comprising generating an ion depletion zone proximate to a sensing electrode by applying an electric field across an ion exchange membrane, wherein the sensing electrode is electrically connected to a gate terminal of the FET.

40. A method for detecting a target analyte, the method comprising:providing a biosensor device comprising a field-effect transistor (FET) having a sensing electrode electrically connected to a gate terminal of the FET;introducing a sample containing the target analyte into the biosensor device; capturing the target analyte on the sensing electrode; andmeasuring an electrical characteristic of the FET to detect the target analyte.

41. The method of claim 40, wherein the target analyte comprises a microRNA.

42. The method of claim 41, wherein the microRNA comprises at least one of miR-21, miR-9, or miR-101-5p.

43. The method of claim 40, wherein the target analyte comprises a nanocarrier.

44. The method of claim 43, wherein the nanocarrier comprises extracellular vesicles.

45. The method of claim 44, wherein the extracellular vesicles are detected using one or more charged reporter particles.

46. The method of claim 44, wherein the extracellular vesicles comprise surface proteins comprising CD63, CD81, or a combination thereof.

47. The method of claim 46, wherein the surface proteins of the extracellular vesicles comprise disease-associated protein biomarkers.092012-0079-W00148. The method of claim 40, wherein measuring the electrical characteristic of the FET comprises measuring a transfer characteristic curve by sweeping a gate voltage while maintaining a fixed drain-source voltage.

49. The method of claim 48, wherein measuring the transfer characteristic curve comprises operating the FET in a subthreshold regime.

50. The method of claim 40, wherein the biosensor device further comprises a microfluidic channel positioned adjacent to the sensing electrode, and an ion exchange membrane (IEM) positioned within or adjacent to the microfluidic channel.

51. The method of claim 50, further comprising applying an electric field across the IEM to generate an ion depletion zone proximate to the sensing electrode.

52. The method of claim 51, wherein applying the electric field comprises applying a DC voltage of about 5 V to about 200 V across the IEM.

53. The method of claim 51, further comprising incubating the sample on the sensing electrode for a period of about 30 minutes to about 60 minutes prior to applying the electric field.

54. The method of claim 51, wherein generating the ion depletion zone reduces local ionic strength from about 150 mM to below about 0.001 mM, thereby increasing an effective Debye length to greater than about 100 nm.

55. A biosensor system, comprising:a biochip comprising a chip substrate, an inlet, an outlet, and a plurality of sensors; a field-effect transistor (FET) electrically connected to at least one of the plurality of sensors; anda measurement circuit configured to measure drain current of the FET as a function of gate voltage.092012-0079-W00156. The biosensor system of claim 55, wherein the biochip further comprises a microfluidic channel extending between the inlet and the outlet, at least one buffer reservoir, and an ion exchange membrane (IEM) positioned beneath the at least one buffer reservoir, the plurality of sensors being positioned within the microfluidic channel.

57. The biosensor system of claim 56, further comprising a voltage source configured to apply an electric field across the IEM to generate an ion depletion zone within the microfluidic channel.

58. The biosensor system of claim 56, wherein the biochip comprises a pair of buffer reservoirs positioned at opposite ends of the microfluidic channel, and wherein the IEM comprises a cation exchange membrane or an anion exchange membrane positioned beneath each of the buffer reservoirs.

59. The biosensor system of claim 58, further comprising platinum electrodes positioned within the pair of buffer reservoirs and configured to receive a DC voltage of about 5 V to about 200 V from a voltage source.

60. The biosensor system of claim 55, wherein the plurality of sensors comprises gold electrodes functionalized with probe molecules configured to selectively bind target biomolecules.

61. The biosensor system of claim 60, wherein the probe molecules comprise at least one of nucleic acid probes or antibodies.

62. The biosensor system of claim 55, wherein the measurement circuit is configured to operate the FET in a subthreshold regime to maximize sensitivity to surface charge perturbations induced by biomolecular binding events.

63. A method for enhancing sensitivity of a field-effect transistor (FET) biosensor, the method comprising:providing a FET biosensor having a sensing electrode functionalized with probe molecules for capturing target biomolecules;092012-0079-W001positioning an ion exchange membrane (IEM) within a microfluidic channel adjacent to the sensing electrode of the FET biosensor;introducing a sample into the microfluidic channel; andapplying an electric field across the IEM to deplete ions from a region proximate to the sensing electrode, thereby increasing an effective Debye length and enhancing electrostatic coupling between the target biomolecules and the sensing electrode.

64. The method of claim 63, wherein applying the electric field comprises applying a DC voltage of about 5 V to about 200 V across the IEM.

65. The method of claim 63, wherein depleting ions from the region proximate to the sensing electrode reduces local ionic strength from about 150 mM to below about 0.001 mM.

66. The method of claim 63, wherein the effective Debye length is increased to greater than about 100 nm.

67. The method of claim 63, wherein the probe molecules comprise at least one of nucleic acid probes configured to hybridize with target microRNA sequences or antibodies configured to bind target protein markers.

68. The method of claim 63, further comprising measuring a transfer characteristic curve of the FET biosensor by sweeping a gate voltage while maintaining a fixed drain-source voltage, wherein the FET biosensor is operated in a subthreshold regime to maximize sensitivity to surface charge perturbations.

69. Use of a biosensor device for detecting target biomolecules in a physiological sample, the biosensor device comprising a field-effect transistor (FET) having a sensing electrode, a microfluidic channel, and an ion exchange membrane (IEM), wherein an electric field is applied across the IEM to generate an ion depletion zone proximate to the sensing electrode to reduce ionic strength and extend Debye length during detection.

70. The use of claim 69, wherein the target biomolecules are charged and comprise at least one of microRNA, extracellular vesicles (EVs), supermeres, exomeres, lipoproteins, proteins, or viruses.